AUTHOR INDEX

Aaronson, S. A. 119, 121
Abdukarimov, A. 191
Abonyi, M. 72, 75, 76, 77, 78, 81, 82
Abraham, E. 107, 346
Abravaya, K. 382
Ackerman, P. 226
Adachi, Y. 373
Adams, J. C. 40
Adams, S. R. 129
Adams-Pearson, C. 214
Adler, M. 376
Adylova, A. T. 191
Agbunag, R. V. 165, 166
Agostinis, P. 215
Ahmad, Z. 205
Ahmed, S. A. 269
Aitken, A. 205, 360
Akerboom, T. P. M. 373
Akiyama, T. 119
Akman, T. S. 58
Al-Alawi, N. 240
Albrecht, A. M. 409
Alden, R. A. 404
Alemany, S. 356
Alenty, A. 402, 409
Alessi, D. 203, 204, 208, 212
Alexander, P. 173, 183, 184
Aliyev, B. M. 191
Allegra, C. J. 57, 58, 60, 73, 75
Alleman, R. K. 269
Allison, A. C. 108, 115
Amalric, F. 238
Amsbaugh, C. 119
Ananthanarayanan, M. 373
Anderer, F. A. 238
Andersen, R. D. 162
Anderson, D. 216
Anderson, R. G. W. 363, 408, 409
Andersson, S. 386
Angel, P. 138, 262, 381, 384, 385, 386, 387, 391
Angeles, S. M. 408
Ansorge, A. 227, 228, 232, 233, 234
Ansorge, W. 226, 228, 230, 238, 227, 233, 240
Antipenko, A. E. 174
Antipenko, A. Ye. 178
Antipenko, Ye. N 187, 189, 183, 191, 185, 188
Antonucci, A. 133
Aoki, T. 21
Aoyagi, K. 181
Aranda, A. 183
Arceci, R. J. 371
Ardalan, B. 58, 59
Arias, I. M. 371, 373
Arlett, C. F. 190
Arnberg, A. C. 42
Arndt, K. T. 218
Arnér, E. S. J. 10, 14, 17, 18, 19, 20, 21
Arredondo, M. A. 65
Aruoma, O. I. 175, 176
Asayama, K. 180
Ashcraft, E. 8, 14
Ashford, V. A. 269, 270, 285, 290
Asins, G. 200
Asta, L. 184
Astwood, E. B. 187
Auer, H.-P. 385, 386, 387, 391, 381, 382
Auger, K. R. 247, 251, 129
Avruch, J. 387
Axton, J. M. 218
Azzi, A. 257
Azzolina, B. A. 100, 114

Baccanari, D. P. 411
Bachmann, M. 138
Badcoe, I. 281, 282, 283
Bae, Y.-S. 238, 240
Baffet, G. 40
Baker, D. G. 187
Balacs, T. 164
Baldin, V. 238
Baldwin, J. E. 335, 346, 347
Baldwin, R. L. 269
Balkman, C. 184
Ball, R. K. 258, 260
Ballou, D. P. 100
Ballou, L. M. 204, 216
Baltimore, D. 269
Bambara, R. A. 138
Banfic, H. 130, 132, 133, 137, 138, 139
Bannister, R. M. 161
Bannister, R. O. 163
Bapat, A. R. 58
Bar-Sagi, D. 137
Barbacid, M. 249
Barber, J. R. 385
Barbour, K. W. 58
Bareggi, R. 134
Bargmann, C. I. 119

Barker, P. J. 130, 138, 139
Barkin, J. S. 58
Barnabei, O. 130, 132, 139
Barnes, P. J. 175
Barnett, C. J. 59
Barr, M. 387
Barry, C. D. 272
Barton, G. J. 269, 272, 290, 275, 331, 291
Baskin, F. 57, 60
Basnakyan, A. G. 173, 183, 184
Basrur, V. R. 187
Bassett, M. 240
Bassin, R. H. 247
Bast, A. 175, 176, 192, 173, 185
Basu, S. K. 363
Batra, J. K. 120, 121
Battifora, H. 119
Batzer, A. 137
Bauer, G. 27
Baugh, C. M. 407
Baumann, I. 386
Baumgartner, S. 214, 215, 218
Bayer-Helms, H. 39
Bazan, J. F. 269, 272
Beacham, L. D. 14
Beacham, L. M. 1, 8
Bedeiti, C. D. 376
Bedell, C. R. 404, 410
Been, W. 34, 41, 44
Beer, J. Z. 381
Beham, R. A. 356
Behrens, N. D. 100, 114
Beintema, J. J. 274, 275
Belagaje, R. 347
Belenguer, P. 238
Belfrage, P. 355, 358, 364, 365, 356, 357, 360, 361
Bell, G. I. 227
Bell, J. I. 200, 202, 214
Belyakova, N. V. 183
Belzer, F. O. 115
Benedetto, P. 58
Benedict, W. F. 159
Benevolensky, D. 173
Benezra, R. 165
Bengtsson, G. 359
Benkovic, S. J. 405, 411
Benner, A. 269, 272, 290, 298, 299
Benner, S. A. 269, 270, 271, 272, 275, 281, 284, 285, 287, 289, 294, 296, 299, 306, 307, 316, 331
Bennett, A. L. 27, 30
Bennett, J. M. 16
Bennett, P. 164, 227
Bensaid, M. 238
Berberich, S. J. 226
Berdel, W. E. 262
Berezney, R. 130, 138
Berg, J. M. 251
Berger, F. 58
Berger, F. G. 57, 60
Berger, M. S. 119
Berger, S. H. 57, 60, 58
Berger, U. 371, 372, 373, 374
Berggren, P. O. 138
Berghlz, E. 233
Berkowitz, D. B. 290
Bernbäck, B. 359
Berne, M. 58
Bernstein, L. 58
Bernstein, M. H. 184
Berra, E. 238
Berridge, M. J. 130
Bertagnolo, V. 130, 131, 132, 133, 136, 139
Berterman, J. 138
Bertino, J. R. 399, 409, 413, 402, 407, 408, 410, 58
Bertrand, M. 58
Beta, E. H. 186, 187
Beullens, M. 202, 204, 213
Beutler, E. 15, 22
Bewley, J. R. 59
Bhalla, K. 8
Bialojan, C. 202
Bidwai, A. P. 231
Biedler, J. L. 409
Bilbe, G. 214
Billi, A. M. 134
Binétruy, B. 388
Bircher, J. 28
Bird, R. E. 120, 121
Birge, R. B. 269
Birkett, D. J. 161
Birkinshaw, J. H. 107
Birren, B. W. 162
Birrer, M. 388
Bishop, J. A. M. 59
Bishop, J. M. 119
Bishop, M. J. 247
Bisschop de, N. 240
Bissell, M. J. Schrode, W. 40
Bisset, G. M. F. 59
Bjorgell, P 356
Bjorkling, F. 360
Bläckberg, L. 358, 359
Blackwell, T. K. 165
Blair, O. C. 80
Blakley, R. L. 402, 403, 405
Blanchard, J.-M. 240
Blanchette-Mackie, E. J. 365, 366
Blas, S. D. 184, 185
Blau, H. M. 46
Blayney, D. 58

Blenis, J. 257, 388
Blokhin, A. V. 390
Blumberg, P. M. 257, 264
Blumenthal, D. K. 226
Blundell, T. L. 287
Boarman, D. M. 58
Bock, K.-W. 45
Bodenback, L. 228, 229, 230, 236, 231
Boesch, D. 371, 376
Bohman, C. 1, 8, 14, 17, 19, 21
Böhme, M. 371, 372, 373, 376, 377
Boldt, D. H. 16
Boldyreff, B. 226, 227, 233
Bolin, J. T. 404, 405, 410
Bollen, M. 199, 202, 204, 213, 214, 216, 200
Bollinger, P. 371, 376
Bonde, B. G. 191
Bondor, J. A. 204, 209, 211, 206
Boone, T. 270
Boonstra, J. 132, 136
Bordwell, K. L. 365
Borek. C. G. 189, 192
Borst, P. 371
Borthwick, A. C. 356, 357
Bos, J. L. 387
Bosch, A. 385
Boscoboinik, D. 257
Boscott, P. E. 275
Boswell, D. R. 270
Botstein, D. 137
Bouche, G. 238
Bouffard, D. Y. 8
Bourel, D. 40
Bourgeois, S. 164
Bourne, H. R. 91
Boyle, J. M. 71, 77, 84
Boyle, W. J. 138, 386
Bozhko, A. P. 180
Bradfield, C. A. 165
Bradford, M. M. 93, 260
Bradshaw, Jr, H. D. 14
Brady, C. E. 28
Brady, L. 358
Bramson, H. N. 286
Brandhuber, B. J. 270
Brant, D. A. 276
Brautigan, D. L. 207, 217
Bravo, R. 385
Brechot, C. 42
Breed, J. 269, 272, 290, 331
Brenner, M. A. 183, 184
Bresnick, E. 76
Breton, M. 132, 136
Brewer, G. 42
Brewis, N 200, 202, 214
Brik, H. 185
Britsch, L. 307
Broach, J. R. 214
Brodie, G. 184
Brooks, B. 164
Brooks, B. A. 164, 167
Brosjö, O. 14, 18, 19, 20
Brown, M. 59, 411
Brown, M. S. 363
Brown, P. C. 371
Brown, S. L. 59
Browning, K. S. 202
Bruckner, H. W. 58
Bruder, J. T. 385, 386, 387, 391
Brugge, J. S. 269, 291, 307, 257
Bryan, J. 14
Brzozowski, A. M. 358, 360
Buchanan, J. M. 399
Büchler, M. 371, 372, 373, 376
Buchmann, A. 45
Buechler, J. A. 286
Buechler, V. J. 129
Bunni, M. 58
Burbach, K. M. 165
Burchall, J. J. 410
Burgen, A. S. V. 403
Burger, H.-J. 28, 29, 33, 30, 32, 44
Burgoyne, L. A. 173, 183, 184
Burke, M. T. 411
Burlakova, E. B. 175
Burlakova, Ye. B. 180, 182, 187, 190
Burnette, B. 205
Burow, E. 226, 228, 229, 231
Burridge, J. M. 410
Busbee, D. L. 138
Büscher, M. 259, 261, 384, 386, 387, 388
Buschman, E. 371
Butle, J. S. 258
Butler, J. 175, 176
Buxton, J. 226, 234

Calvert, A. H. 59, 411, 65, 200
Camici, M. 205
Camier, S. 214
Campbell, A. K. 182
Campbell, D. G. 205, 211, 356
Campbell, G. A. 183, 184
Campbell, I. G. 408
Campbell, J. W. 27
Campbell, K. E. 42
Canaani, D. 227, 233, 234
Cannon, J. F. 208
Cantley, L. C. 247, 251, 129
Cao, S. 121
Capitani, S. 130, 132, 138, 134, 133, 139
Carbone, A. 258
Carini, C. 132

Carlin, S. C. 57, 60
Carling, D. 356
Carlsson, G. 58
Carpenter, C. 247, 251, 129
Carr, B. 58
Carramanzana, N. 162, 163
Carrera, C. J. 20, 22, 15
Carroll, D. 240
Carson, D. A. 15, 22, 20
Carter, G. L. 2
Carter, S. B. 107, 114, 100
Casanova, S. 183
Cashmore, A. 410
Casper, E. S. 59
Cassalino, E. 180
Castagna, M. 257, 264
Cataldi, A. 133
Cato, A. C. B.
Caudwell, F. B. 205, 211
Cavadore, J.-C. 240
Chabner, B. A. 58, 59, 73, 75, 84
Chader, G. J. 36
Chakravarty, P. K. 269
Chalfie, M. 233
Chalovich, J. M. 2, 3, 4, 5, 8
Chambaz, E. M. 238
Champness, J. N. 404, 410
Chamuleau, R. A. F. M. 27, 28, 31
Chang, K. J. 138
Chang, M.-K. 365
Chapkin, R. S. 238
Chapman, J. L. 347
Charles, R. 27, 30, 31, 28, 44, 42
Charnock, J. M. 347
Chattopadhyay, S. K. 95
Che, M. 371, 373
Chebotaryov, Ye. Ye. 187, 189
Chen, C.-H. 8
Chen, I. S. 1, 8, 14
Chen, J.-T. 405
Chen, P. 411
Chen, R. H. 129
Chen, V. J. 346, 347
Chen-Wu, J. L.-P. 227
Cheng, Y.-C. 1, 5, 8
Chenoweth, M. E. 36
Cheshire, P. J. 58
Cheson, B. D. 16
Cheung, M. C. 227
Chiang, T. 189
Chida, K. 257
Chisholm, A. A. K. 205
Chiu, R. 384
Choi, W. C. 132
Chothia, C. 274, 287
Chottiner, E. G. 8, 14
Chou, P. Y. 270, 272
Christa, L. 42
Christiansen, L. 358
Chrivia, J. C. 227
Chu, F.-F. 164, 167, 163
Chu, N. 108, 112, 113
Chua, L. 58
Chubb, C. B. 92, 96, 103
Chujoh, Y. 165
Chung, L. W. K. 39
Ciardelli, T. L. 270, 272
Cichowicz, D. 407
Cicirelli, M. F. 226
Clark, G. M. 119, 121
Clark, J. L. 57
Clement, B. 40
Cline, J. C. 107, 114
Cline, M. J. 119
Coates, J. B. 335
Cobb, M. H. 386
Cocco, L. 131, 132, 133, 139, 136, 138, 130, 134, 135, 137, 405
Cochet, C. 238
Cohen, F. E. 270, 272
Cohen, M. A. 270, 275, 276, 277, 298, 315, 307
Cohen, P. 204, 207, 211, 212, 216, 356, 357
Colbran, R. J. 356, 364
Colcher, D. 121
Cole, M. D. 226
Coleman, J. E. 251
Collart, F. R. 91, 96, 103, 110
Collins, J. M. 73, 75
Collins, K. D. 58, 60
Colloc'h, N. 273, 292
Coney, L. R. 408
Conley, L. 164
Conley, L. H. 164, 167
Conn, H. O. 28
Conney, A. H. 162
Connolly, P. J. 269
Conrad, P. A. 227
Contente, S. 247
Cook, J. 407
Cook, J. M. 108, 114, 107
Cook, K. G. 355, 364, 365
Cooke, E. 181
Coon, H. G. 160
Coon, M. J. 162
Cooney, D. A. 79, 96
Cordle, S. R. 356, 364
Corlu, A. 40
Cory, A. H. 2, 3, 4, 5, 8
Cory, J. G. 2, 3, 4, 5, 8
Cosman, D. 270, 272
Cosulrich, D. B. 399
Coulson, A. R. 248, 250

Covello, C. 184
Cowan, N. J. 233
Cowburn, D. 269
Cranford, S. K. 58
Crawford, E. J. 402, 409
Crawford, I. P. 269, 272, 275, 277
Crews, C. M. 216
Cripps-Woldmann, J. 138
Cron, P. 214
Croop, J. M. 371
Cruise, J. 46, 50
Cuatracasas, P. 138
Cullinan, S. A. 58
Cunha, G. R. 39
Curran, T. 385
Curtin, G. M. 138
Curtis, B. M. 270, 272
Cuthill, S. 166
Cutler, L. 247
Cygler, M. 358
Czajbowski, C. A. 408
Czech, M. P. 226, 234, 235, 240
Czyzyk, L. 383

D'Arcangelo, G. 257
D'Arcy, A. 358, 404
Daddona, A. 132, 133
Daddona, P. E. 8
Daeumigen, M. 269
Dählback, H. 386
Dalgarno, D. C. 291
Danenberg, P. V. 58
Danielsen, M. 164
Danielson, K. G. 258
Dann, J. G. 403, 404, 410
Darnell Jr, J. E. 27, 30, 33, 44
Das, A. T. 42
Datta, M. W. 14
Datta, N. S. 8, 14
Davies, D. R. 269
Davis, D. N. 386
Davis, F. B. 184, 185
Davis, P. J. 184, 185
Davis, R. 165
Davis, W. 59
Dayhoff, M. O. 275, 277, 279
De Boer, P. A. J. 31, 32, 44
De Graaf, A. 27
De Groot, C. J. 27, 31
De Haan, J. G. 31
De La Haba, D. S. 191
De Vita Jr, V. T. 84
De Vose, A. M. 269
De Vries-Smits, L. 385
Dean, E. 233
Dean, R. T. 175, 178
Deboer, P. A. J. 27
Debov, S. S. 183
Defize, L. H. K. 138, 386
Degrado, W. F. 269
Degraw, J. I. 411
Deierhoi, M. H. 115
Deininger, P. L. 14
Del Coco, R. 130, 132, 134, 137
Delap, R. 58
Deli, E. 130
Delius, H. 386
Delong, C. 107, 114
Demaille, J. G. 286
Demain, A. L. 307
Demarco, M. 257
Dembo, M. 406, 407
Deng, T. 240
Denhardt, D. 248
Denis, C. L. 129
Denis, M. 166
Denison, M. S. 166
Dent, P. 211
Denton, J. E. 21
Deodhar, S. D. 189
Depaoli-Roach, A. A. 205, 211, 212, 214, 215, 217, 218
Der, R. 258
Derewenda, U. 360
Derewenda, Z. S. 358, 360
Derua, R. 215
Desmet, J. M. 376
Desvergne, B. 183
Deuel, T. F. 46
Devary, Y. 385, 387, 388
Dhar, M. M. 269
Di Primio, R. 134
Diamond, L. 159
Diamond, L. K. 399
Diaz-Meco, M. T. 238
Didier, A. D. 371, 376
Didonato, J. A. 388, 389
Diep, A. 164
Diethelm, A. 115
Difiore, P. P. 119, 120
Dingwall, C. 130
Dion, R. L. 79
Divecha, N. 130, 132, 133, 137, 138
Dizhe, G. P. 174, 178
Dobashi, K. 180
Dodd, S. W. 121
Dodson, E. 358
Dodson, G. 358
Dodson, G. G. 358, 360
Doelman, C. J. A. 175, 176, 192
Dollard, C. A. 129
Dolnick, B. J. 57, 60
Dombradi, V. 218

Dominguez, I. 238
Donehower, C. R. 59
Donohue, D. R. 402, 409
Doonan, J. H. 218
Doppler, W. 258, 260
Dorn, A. 138
Doroshow, J. H. 58
Doson, G. G. 360
Dospmann, W. 286
Dotzlaf, J. E. 307
Downward, J. 387
Drake, J. C. 57, 60, 58
Drew, R. 161
Driscoll, M. 233
Drubin, D. G. 137
Dubinin, N. P. 183
Duckworth, B. 247, 251, 129
Duffy, T. H. 412
Dumont, M. 376
Dunlap, R. B. 402, 403
Dunn, A. 35, 36, 46, 39
Dunphy, W. G. 217
Durban, E. M. 258
Durgerian, S. 286
Durham, J. P. 13, 14
Durnov, A. D. 192
Duyndam, M. 385
Dvoretzky, I. 95

Ebert, A. 27
Ebert, D. 386
Eble, J. N. 21, 73, 79, 80
Eddy, R. 233
Edelman, A. M. 199, 226
Egan, E. F. 57, 60
Egan, J. J. 365, 366
Egui, E. M. 108, 115
Eisen, H. 163
Eisenberg, W. 269
Eisenman, R. N. 226, 240, 251
Eisenmann-Tappe, I. 29, 39
Elhakim, T. 58
Elion, G. B. 1, 8, 14
Eliopoulos, E. 404, 410
Elledge, S. J. 387
Ellington, A. D. 270, 274
Elliott, W. L. 71, 77
Ellis, C. 216
Elswick, B. 40, 41
Elwood, P. C. 408
Ema, M. 165
Emanuel, N. M. 180
Emmerik van, N. 408
Emmison, N. 356, 357
Emrani, J. 71, 72, 81, 83
Endicott, J. A. 371
Engelhardt, J. A. 59
Epinette, W. W. 108
Epstein, L. B. 270, 272
Erba, H. P. 233
Erickson, J. S. 405
Erickson, L. C. 61, 62
Ericsson, L. H. 226, 286
Erikson, E. 216
Erikson, R. L. 216
Eriksson, S. 14, 17, 18, 19, 20, 21, 1, 8, 10
Erlichman, C. 58
Erlinger, S. 376
Eshita, S. M. 269
Esswein, A. 414
Estabrook, R. W. 162
Esteller, A. 376
Esterman, M. A. 107, 108, 114
Etchebest, C. 273, 292
Evans, R. M. 58, 251
Everson, L. K. 58
Everson, T. P. 59
Ewig, R. A. G. 61, 62

Faderan, M. A. 71, 77, 79
Fahrner, J. 42, 43
Falcieri, E. 138
Fan, H. 241
Fan, J. 407, 408
Farber, S. 399
Farr, A. L. 3
Fasman, G. 269, 272, 286
Fausel, M. 29
Fauss, J. 228, 229, 231
Feeney, J. 403
Ferenci, P. 28
Fernandes, D. J. 58
Fernandez, A. 258, 262, 264, 207
Fernandez, D. L. 207, 217
Fey, E. G. 136
Fields, A. P. 130
Fierke, C. A. 405
Filhol, O. 238
Filman, D. J. 404, 405, 410
Fine, S. 58
Finer-Moore, J. S. 411
Fink, G. R. 218
Finkelstein, A. V. 272
Finlay, C. A. 92
Fiol, C. J. 205, 211, 212
Fischer, E. H. 204, 286
Fischer, G. A. 1, 8, 13, 14, 402, 409
Fiskum, G. 184
Fitzgerald, D. J. P. 120, 121
Fitzke, H. 27, 30, 29
Flora, S. De. 189

Flores, T. P. 270, 290, 294, 295, 305
Flory, P. J. 276
Fojo, A. 371
Fook-Thean Lee, 205, 208
Foon, K. A. 16
Forkmann, G. 307
Fornace, A. J. 381, 382
Fort, D. W. 408
Foulkes, J. G. 200
Foulkes, W. D. 408
Fox, B. G. 347
Fox, I. H. 1, 8, 14
Fox, M. 71, 77, 84
Fox, R. M. 58
Fox, S. P. 206
Foxwell, B. M. J. 371
Francois, J. M. 211
Franklin, T. J. 107, 114, 100, 108, 110
Frasca, V. 408
Fredrikson, G. 355, 358, 364, 365
Freeman, M. 72, 402
Freer, S. T. 404
Freese, E. 42, 43
Freisheim, J. A. 408
Freisheim, J. H. 402, 403, 405
Fridovich-Keil, J. L. 14
Friedkin, M. 402, 409, 57, 60
Friedman, J. 272
Friedman, R. M. 247
Friis, R. R. 258
Frijters, C. 42
Fritsch, E. F. 248
Frolik, C. A. 346, 347
Frosing, R. 58
Frost, J. 240
Fry, D. C. 286
Fry, D. W. 58
Fuglsang, A. 212
Fujii, H. 39
Fujii, K. 412
Fujii-Kuriyama, Y. 163, 165
Fujishima, Y. 347
Fujiwara, Y. 190
Fukami, K. 134, 137
Fukumoto, Y. 258, 264
Funae, Y. 165
Fung, E. 91, 93
Furt, E. 27
Furuno, J. 184
Futterman, S. 401
Fyodorov, V. K. 180, 181
Fyodorova, A. A. 187, 189

Gaasbeek, J. W. 30
Gaasbeek Janzen, J. W. 27, 28, 30, 31
Gabrio, B. W. 402, 409
Galanzi, A. 134
Gangl, A. 28
Garbay, J. 48, 49, 50
Garner, A. 175, 178
Garner, C. D. 347
Garnier, J. 271, 272, 274, 291, 294, 298
Garton, A. J. 356, 361
Garty, N. B. 365, 366
Gatmaitan, Z. 371, 373
Gatti, R. A. 164
Gaunitz, C. 42, 43
Gautam, N. 91
Gauthier-Rouviere, C. 258, 262, 264
Gavériaux, C. 371, 376
Gaziev, A. I. 184
Gebel, S. 385, 386, 387, 391, 381, 382
Gebeyehu, G. 79
Geddes, A. J. 404, 410
Geerts, W. J. C. 27, 42
Gehring, U. 164
Gelbion, H. V. 159, 160, 162
George, S. 407
Geppert, T. D. 386
Gerace, L. 137
Gerloff, D. 269, 270, 271, 272, 275, 281, 284, 285, 287, 289, 294, 296, 299, 306, 307, 316, 331
Gerloff, D. L. 269, 270, 272, 287, 290, 298, 331
Germain, G. 58
Gerok, W. 27, 28
Geurts van Kessel, A. 227, 233
Geuze, H. J. 134, 137
Gharehgbaghi, K. 115
Gibbs, C. S. 42
Gibson, K. 59
Gibson, T. 269, 272, 307
Gibson, W. 59, 411
Gielen, J. E. 159
Gillette, J. R. 162
Gilman, M. 264, 265, 385
Gilmartin, M. E. 233
Gilmour, R. S. 130, 131, 132, 133, 136, 139
Ginsburg, D. 8, 14
Giovanni, R. De 184
Giralt, M. 183
Girard, P. R. 130, 138
Glaise, D. 40
Glazer, R. I. 79
Glimelius, B. 58
Glinsmann, W. H. 200
Glomset, J. A. 362
Glover, C. V. C. 231, 226, 227
Glover, D. M. 214, 215, 218
Glover, E. 160
Glover, J. L. 21, 73

Gobbi, P. 138
Godolphin, W. 119, 121
Goebl, M. 214, 215, 218
Goldberg, D. 58
Goldblum, R. 115
Goldfine, I. O. 183
Goldin, A. 402, 409
Goldman, I. D. 406, 407
Goldstein, B. I. 179
Goldstein, J. L. 363
Gomes, R. 214, 215, 218
Gomez, N. 216
Goncharova, R. I. 192
Gong, M. C. 212
Gonnet, G. H. 270, 275, 276, 277, 298, 315
Gonwa, T. A. 115
Gonzalez-Buitrago, J. M. 376
Goodacre, J. A. 355, 363
Goodburn, S. 129
Goodwill, C. M. 189
Goraj, K. 269
Gorgas, K. 371, 372, 376, 377
Goris, J. 204, 214, 215, 216
Gorman, C. M. 386
Gorodetskaya I. V. 180
Gosio, B. 107
Gossett, L. S. 59
Goto, I. 48
Gotoh, O. 165
Gotoh, Y. 216
Gottert, E. 227, 233
Gottesman, M. M. 371
Gottlieb, R. A. 385, 387, 388
Govorova, N. Yu. 174
Grabowski, P. J. 232
Graf, W. 58
Graham, R. 264, 265, 385
Gralla, R. J. 411
Grant, S. 8
Graziani, A. 129
Graziani, A. J. 247, 251
Gready, J. E. 402, 403, 405
Greco, W. R. 61
Green, M. D. 58
Greenberg, A. S. 365, 366
Greenberg, G. R. 400
Greengard, O. 30
Greist, M. C. 108
Grem, J. L. 58
Grever, M. R. 16
Gribben, D. 8, 14
Grief, R. L. 184
Grindey, G. B. 59
Groff, J. P. 405
Groner, B. 258, 259, 260
Gros, P. 371
Grossman, L. 182, 183
Grover, B. 119
Gruber, H. E. 92, 96, 103
Gruenstein, E. 180
Grummit, I. N. 240
Grundler, G. G. 412
Grunicke, H. 260, 262, 387
Gu, L. 108, 112, 113
Gubler, U. 248
Gudas, J. M. 14, 161, 162, 163
Guernsey, D. L. 189
Guguen-Guillouzo, C. 40
Guillouzo, A. 40
Guimaraes, M. A. 65
Gukasov, V. M. 180, 181
Gulbis, B. 376
Gullick, W. J. 119
Gumucio, J. J. 28
Gundersen, L. E. 402, 403
Gunnung, P. 233
Gunvén, P. 14, 18, 19, 20
Gurney, A. L. 183
Gusella, G. L. 258
Gustafsson, J.-A. 39, 166
Gustavsson, B. G. 58
Gutman, A. 258, 263
Gutte, B. 269
Gutteridge, J. M. C. 192
Guzelian, P. S. 40, 41
Gwo-Shu Lee, M. 233

Habteyesus, A. 1, 8, 14, 17, 19
Haenen, G. R. M. M. 175, 176, 192, 185
Haenseler, E. 414
Hagen, U. 190
Hagmeyer, B. M. 386
Hahn, K. W. 269
Hajnal, A. 247
Hakala, M. T. 58, 402, 409
Hakimi, P. 183
Haleem-Smith, H. 42, 43
Halegova, S. 257
Haley, J. 227
Hall, A. 257
Hall, J. L. 233
Hall, T. C. 406
Hallett, H. B. 181
Halliwell, B. 175, 176, 192
Hamada, H. 233, 371
Hameister, H. 227, 233
Hamlin, R. C. 404, 405
Hanafusa, H. 269
Handel, Jr, T. 269
Handschumacher, R. E. 58
Hankinson, O. 160, 161, 162, 163, 164, 165, 166, 167

Hanna, D. E. 227
Hannah, R. 163
Hansch, C. 404
Hansen, G. 408
Hanson, R. W. 183
Harden, D. 190
Hardestry, B. 204
Hardie, D. G. 356, 357
Harding, N. G. L. 402, 403
Hardman, K. D. 120, 121
Hardy, L. W. 411
Harel-Bellan, A. 263
Harkrader, R. J. 21
Harootunian, A. T. 129
Harpel, M. R. 346, 347
Harrap, K. R. 59, 65
Harris, C. C. 91
Harris, R. S. 399
Harris, T. J. R. 42
Harrylock, M. 226
Harstrick, A. 58
Harvey, D. M. 92, 93
Haseman, J. H. 205, 211, 212
Hashimoto, T. 307
Hashimoto, Y. 71, 72, 81, 83
Hata, Y. 72, 75, 76, 77, 78, 81, 82
Hattori, K. 384
Häussinger, D. 28, 44
Hayashi, J. 39
Hayashibe, H. 180
Hayes, A. A. 58
Hayter, A. J. 59
Hayward, B. E. 42
He, G. 121
Healy, A. M. 214, 215, 218
Hecht, F. 190
Hecht, M. H. 269
Hecht, R. 227
Hedstrom, L. 107
Heelan, R. T. 411
Heerema, N. 79, 80
Hegardt, F. G. 200
Heini, H. 30, 32, 44
Heinzmann, C. 164, 356, 358, 361
Heller, R. A. 364
Heller-Harrison, R. 226, 234, 235
Hellman, S. 84
Hemmings, B. A. 214, 215, 218, 227, 356, 204
Henderson, G. B. 407
Hendrix, P. 214, 216
Henning-Chubb, C. 110
Henrissat, B. 273, 292
Hensey, C. 257
Herfarth, C. 371, 372, 376, 377
Hermann, J. 215, 216
Hernell, O. 358
Hernshaw, E. C. 138
Herr, I. 386
Herr, S. 230, 240
Herrera, H. O. 58
Herrera, R. E. 384
Herrlich, P. 385, 386, 387, 391, 259, 381, 382, 384, 390
Herrmann, D. H. J. 262
Herschman, H. R. 258
Hertel, L. 14
Hertz, R. 399
Hess, M. L. 175, 177
Hetzel, B. S. 191
Hewitt, N. A. 227, 228, 230, 233
Hiddenmann, W. 58
Hidziak, R. M. 119
Hieber, L. 381
Hiken, J. 205
Hilberts, A. 27
Hines, J. D. 57, 60
Hinkle, L. E. 191
Hiraga, A. 209
Hirsch, A. H 365
Hirschmann, P. 240
Hirsh, D. 233
Hitchings, G. H. 402, 403, 405, 398, 410, 411
Ho, S. P. 269
Ho, Y. K. 363
Hoch, J. C. 269
Hochhauser, S. J. 91, 101
Hodges, S. D. 91, 93
Hoehmann, S. 307
Hoey, B. M. 175, 176
Hoffman, B. J. 248
Hoffman, D. H. 107, 108, 114
Hoffman, E. 164
Hoffman, E. C. 164, 167
Hoffman, E. C. 167
Hoffman, R. 71, 79, 80
Hoflacher, J. 260
Hofmann, J. 262
Hofsteenge, J. 214, 274, 275
Holbrook, N. J. 381, 382
Hollan, S. R. 80
Hollenberg, S. 165
Hollenberg, S. M. 251
Hollstein, M. 91
Holm, C. 356, 358, 361
Holm, E. 28, 30
Holmes, C. F. B. 205, 208
Holst, L. S. 358, 360, 361
Holt, J. A. 119, 121
Holzner, H. 28
Honnor, R. C. 356
Hoogenraad, N. J. 58
Hoppe, J. 231

Horanyi, M. 80
Hori, Y. 258, 264
Horio, M. 371
Hoshi, A. 58
Houck, K. A. 46, 50
Houghton, P. J. 58
Housley, M. D. 238
Housman, D. E. 371
Houssin, D. 376
Howard, B. H. 386
Hoynes, K. E. 36, 44
Hsieh, T. 138
Hsu, J. 371, 373
Hsuan, J. J. 240
Hu, E. 226, 227, 228, 233
Huang, F. L. 138, 200
Huang, K. P. 138
Huang, M. 257
Huang, W. 214
Hubbard, M. J. 204, 207, 211, 212, 216
Huber, B. E. 371
Huber, R. 290
Huberman, E. 92, 96, 103, 110, 159
Huennekens, F. M. 400, 401, 402, 403, 407, 408, 409, 412, 414, 72
Hug, H. 129, 130, 138
Huge-Jensen, B. 358, 360
Hughes, L. R. 59, 411
Hughes, V. 200, 202, 214
Hultquist, M. E. 399
Humphreys, S. R. 402, 409
Hung, M. C. 119
Hunt, T. 269
Hunter, T. 138, 199, 202, 216, 226, 386
Hunziker, W. 358
Hupe, D. J. 100, 114
Hurley, M. C. 1
Huskisson, N. S. 130, 138, 139
Hussain, A. 42
Hyde, C. C. 269
Hynes, N. E. 119

Ichikawa, S. 72, 75, 84
Ikawa, S. 119
Ikebe, M. 203, 204, 212
Ikegami, T. 71, 72, 81, 83
Ilyin, V. S. 184
Ingbar, S. H. 185
Ingebritsen, P. 357
Ingebritsen, T. S. 357, 200
Inglese, J. 411
Ingolia, T. D. 347
Irino, S. 203
Irvine, R. F. 130, 132, 133, 137, 138, 139
Ishiara, H. 136
Ishihara, J. 58
Ishikawa, T. 371, 372, 376, 377
Israel, D. 162, 163
Issinger, O.-G. 226, 227, 233
Iujvidin, S. 14
Ives, D. H. 13, 14
Izumi, T. 217

Jachez, B. 371, 376
Jackman, A. J. 65
Jackman, A. L. 408, 411, 59
Jackson, R. C. 91, 92, 96, 101, 103, 21, 58, 59, 360
Jacobson, J. W. 120
Jadaud, P. 58
Jaggi, R. 259
Jakab, G. 178
Jaken, S. 137, 139
Jakobi, R. 226, 228, 230, 238
James, M. L. 257, 264
Jancarik, J. 270, 272
Jans, D. A. 241
Jans, S. A. 227
Jansen, I. 92, 96, 103
Janzen, R. 30
Jastreboff, M. M. 58
Jayaram, H. N. 1, 8, 115, 71, 84, 79, 73, 80, 84
Jayaram, N. J. 115
Jeffery, E. 270, 272
Jenh, C. H. 57, 60
Jenny, T. F. 269, 270, 272, 287, 290, 298, 331
Jeno, P. 216
Jepson, C. A. 364
Jiang, H. 137
Jiménez, R. 376
Jirtle, R. 29, 33, 34
Jodrell, D. I. 59
Johansson, N. G. 14
Johns, D. G. 79
Johnson, B. 164
Johnson, B. S. 167
Johnson, D. 411
Johnson, K. A. 405
Johnson, L. F. 57, 60
Johnson, R. K. 58
Johnson, S. 120, 121
Johnson, T. R. 129
Johnson, W. C. 269
Johnsson, K. 269, 290
Jolivet, J. 58, 412
Jones, D. F. 107, 114, 100
Jones, D. T. 270, 290, 294, 295, 305
Jones, E. L. 108
Jones, L. A. 119, 121
Jones, L. R. 178, 209

Jones, M. 59
Jones, M. O. 411
Jones, S. 164
Jones, T. A. 408
Jones, T. R. 59
Jonges, G. N. 27
Jonitza, D. 46
Jornvall, H. 386
Judin, G. I. 185, 187, 189, 191
Judson, I. R. 59, 411
Juliusson, G. 14, 18, 19, 20, 16, 22
Jung, W. 29, 41
Jungermann, K. 27, 43

Kabat, E. A. 272
Kabsch, W. 271, 272
Kadmon, M. 371, 372, 376, 377
Kaibuchi, K. 258, 264
Kaina, B. 381
Kaiser, E. T. 269, 286
Kaiser, S. 28
Kaizer, L. 58
Kako, K. J. 175, 176, 177, 178, 179
Kakunaga, T. 233
Kalser, M. H. 58
Kamata, N. 119, 121, 257
Kamen, B. A. 408, 409
Kamen, R. 42
Kamimoto, Y. 371, 373
Kan, Y. W. 227
Kane, M. A. 408
Kannicht, C. 371, 372, 373, 374
Kanzawa, F. 58
Kappeller, R. 247, 251, 129
Karenlampi, S. O. 162, 163
Karin, M. 138, 226, 259, 262, 384, 385, 387, 388, 386, 389
Karlsson, A. 14, 17, 18, 19
Karsanova, I. R. 173, 183, 184
Kasprzyk, P. G. 120, 121
Kathman, I. 408
Kato, K. 180
Kato, M. 257
Katz, K. 137
Katz, N. 27, 43
Katzav, S. 249
Kauffman, M. G. 14
Kauffman, R. S. 115
Kaufman, B. M. 120
Kaufman, B. T. 404
Kaufman, R. J. 409
Käussinger, D. 28
Kavetsky, R. E. 189
Kawasaki, H. 20, 22
Kay, N. E. 16
Keating, M. J. 16
Kedes, L. 233
Keith, D. E. 119, 121
Kelley, J. A. 79
Kelly, F. J. 180
Kelly, T. J. 14, 91, 101, 102, 95
Kempin, S. J. 16
Kende, A. S. 160
Kennan, A. L. 36
Kenney, W. C. 270
Kenyon, K. 247
Keppler, D. 371, 372, 373, 376
Kerc, E. 204, 212
Kernohan, J. C. 204
Kessel, D. 406
Keyomarsi, K. 59
Keyse, S. M. 381
Kezdy, F. J. 269
Khalil, M. 208
Khamidov, D. Kh. 191
Kharchenko, V. P. 191
Kierdaszuk, B. 14
Kiguchi, K. 110
Kikkawa, U. 257, 264, 240, 262
Kim, J. 269, 290, 298
Kim, S.-H. 270, 272
Kimbell, R. 59, 411
Kimura, S. 164
Kinchington, A. 227
King, C. R. 119, 121, 120
King, R. 42, 43
King, S. A. 58
Kinoshita, N. 213, 218
Kinsella, A. R. 71, 77, 84
Kinzel, V. 226, 228, 229, 231
Kipps, T. J. 20, 22
Kirchgessner, T. G. 356, 358, 361
Kirdaszuk, B. 8
Kirk-Bell, S. 190
Kirschner, K. 269, 272, 275, 277
Kirschner, M. W. 216
Kiselyov, F. L. 173, 183, 184
Kishimoto, A. 262
Kiss, Z. 130
Kit, S. 13, 14
Kitagawa, Y. 203
Kitano, M. 373
Kitayama, H. 247
Klein, G. 58
Klein, I. 184
Kleinman, H. K. 40, 41
Klemenz, R. 247
Klett, C. 227, 233
Klinke, R. 270, 272
Klintmalm, G. B. 115
Klis, W. A. 269
Klumpp, S. 357
Klünemann, C. 371, 372, 373, 374

Knecht, L. J. 269, 270, 272, 287, 290, 298, 331
Kneebone, P. 79, 80
Kneip, B. 40
Knighton, D. K. 286
Knighton, D. R. 269, 270, 285, 290
Kobayashi, H. 373
Kobayashi, S. 212
Kobierski, M. E. 59
Koch, C. A. 216
Koerner, D. 183
Kohn, K. W. 61, 62
Koijma, K. 136
Koizumi, S. 382
Kolhouse, J. F. 408
Kominos, D. 269
Konarska, M. M. 232
König, H. 259, 261, 381, 382, 384, 385, 386, 387
Konno, Y. 96
Kopatz, I. 227, 233, 234
Korfage, H. A. M. 31
Kortschot, A. 27, 31
Kosen, P. A. 270, 272
Koshland, Jr, D. E. 270, 272
Kossiakoff, A. A. 269
Koszalka, G. W. 1, 8, 14
Kote, Z. 80
Kovacevic, S. 307
Kovacs, R. J. 178
Koveshnikova, I. V. 183, 191
Kowalczuk, M. 205, 211, 212
Koyama, S. 291
Kraemer, M. 381
Kraft, A. S. 130
Kramer, G. 204
Krämer, M. 381, 382, 387, 389
Kranias E. G. 178
Krasovskaya, I. E. 174
Krasovskaya, I. Ye. 178
Kraus, M. H. 119, 121
Kraus, P. 57, 60
Krause, M. 165, 233
Kraut, J. 404, 405, 410
Krebs, E. G. 226, 227, 231, 234
Kreiger, M. 363
Krek, W. 226, 234, 235, 238
Kremmer, T. 80
Krenitsky, T. A. 1, 8, 14
Kriauciunas, A. 347
Kris, R. M. 240, 411
Krohn, K. 115
Krook, J. E. 58
Krumdieck, C. L. 407
Krutykov, V. M. 183
Kubler, D. 226, 228, 229, 231
Kuby, S. A. 286
Kudlicki, W. 204
Kuenzel, E. A. 226, 240, 251
Kuhn, A. 240
Kuhnt, D. 59
Kukreja, R. C. 175, 177
Kulberg, A. Ya. 181
Kumagai, A. 217
Kumar, M. S. 189
Kumar, S. 286
Kunst, M. 373
Kuntz, I. D. 270, 272
Kunz, E. 387
Kuo, C. F. 27, 30, 42, 43
Kuo, F. C. 33, 44
Kuo, J. F. 130, 138, 262
Kupka, J. 307
Kuret, J. 205
Kuriyan, J. 269
Kuroki, T. 257
Kurumi, Y. 373
Kurz, C. 385
Kurz, G. 371, 372, 373, 374
Kyriakis, J. M. 387

Labbe, J.-C. 207
Labbe, S. 382
Labourdette, G. 138
Labruyere, W. T. 42, 43
Lacey, S. W. 408, 409
Laliberte, J. 8
Lamb, N. J. C. 258, 262, 264, 207, 217
Lambert, M. E. 381
Lambert, M. W. 381
Lamers, W. H. 27, 30, 31, 28, 30, 29, 33, 34, 31, 32, 44
Landriscina, C. 180
Lange, E. 164
Langin, D. 358, 360, 361
Lapis, E. 71, 79, 80
Lark, R. H. 408
Larsen, S. H. 107, 114
Laskey, R. 130
Laskey, R. A. 138
Laskin, J. D. 58
Lasserre, C. 42
Lau, L. F. 388
Laue, T. M. 269
Lauire, J. A. 58
Laurell, H. 358, 360, 361
Laval, J. 381
Lavoinne, A. 211
Lawrence, J. C. 205
Lawrence, J. R. 205
Lawson, D. M. 358, 360
Lawson, J. E. 202
Le Thai, B. 376

Leach, K. L. 257, 264
Leclerc, J. L. 376
Lee, F.-T. 355
Lee, K. 132
Lee, L.-S. 1, 5, 8
Lee, S. M. 120
Lee, S. Y. 132
Lee, T. 120
Lee, T. H. 216
Lee, W. 247
Lee, W. A. 108, 112, 113
Lee, W. M. F. 385
Legaspi, A. 58
Legraverend, C. 39, 162, 163
Lehto, V.-P. 269, 272, 307
Leichman, L. P. 58
Leninger, A. L. 184
Lenmann, A. R. 190
Leno, G. H. 138
Lenstra, J. A. 274, 275
Leonard, B. J. 100, 107, 114
Leone, A. 382
Leong, L. 58
Leray, G. 40
Lesk, A. M. 274, 287, 270
Letcher, A. J. 131, 132, 133, 139
Leung, K. 108, 112, 113
Levin, W. J. 119, 121
Levine, A. J. 92, 93
Levine III, H. 138
Levinson, B. B. 58
Levison, S. A. 402, 403
Levitt, M. 272
Levy, E. J. 58
Lewis, S. A. 233
Lhadi, C. 40
Li, D. 40, 41
Li, M. C. 399
Li, Y. 358
Liang, C. M. 59
Lichter, P. 227, 228, 232, 233, 234
Liddle, C. 39
Liepnieks, J. J. 71, 77, 79
Liliemark, J. 14, 18, 19, 20, 16, 22
Lim, V. I. 272
Lin, A. 240
Lin, B. 1
Lin, C. 385
Lin, C.-K. 35, 36, 46
Lin, C. Q. 40
Lin, J. T. 58
Lin, P.-F. 14
Lindahl, T. 173, 184, 185
Lindros, K. 27, 29
Ling, V. 371
Lippman, M. E. 57, 60
Lipscomb, J. D. 346
Lisio, R. 133
Litchfield, D. W. 226, 227, 231, 234
Litfin, M. 386, 387, 388, 390
Litwin, S. 59
Liu, J. S. 183
Live, Jr, D. 269
Lively, D. H. 107, 114
Livingstone, A. 58
Liychfield, D. W. 251
Lloyd, A. C. 257
Locher, G. W. 119
Loeser, A. 189
Loferer, H. 387
London, R. E. 405
Londos, C. 365, 366
Long, G. L. 286
Long, R. C. 269
Look, K. Y. 81
Loomis, C. 233
Loor, F. 371, 376
Lorenz, P. 226, 228, 230, 238
Los, J. A. 27
Louie, M. 46
Lowry, O. H. 3
Lowy, D. R. 95
Lozano, J. 238
Lozemann, F. J. 226, 227, 231, 234
Lucka, L. 371, 372, 373, 374
Lücke-Huhle, C. 381, 382
Luckow, B. 259
Luetteke, N. C. 46, 50
Lui, M. S. 21, 71, 77, 79, 84
Luscher, B. 226, 240
Lusis, A. J. 356, 358, 361
Lutz, R. 58
Lynch, G. P. 346
Lyons, A. 42
Lyzlova, S. N. 173, 183, 185

Maas, M. A. W. 31
Macara, I. G. 257
Macdougall, M. 203, 204, 212
MacKenzie, R. E. 412
Mackie, A. 371
Macklin, M. D. 227
MacLennan, D. 176
Magnusson, P.-H. 58
Mahrenholz, A. M. 205
Mai, S. 381, 387
Mailliard, J. A. 58
Majerus, P. W. 137
Major, H. 205, 208
Maller, J. L. 217
Mallick, U. 381, 390
Malmberg, M. 58
Malotoni, C. 59

Maltzman, W. 383
Malviya, A. N. 138
Maly, K. 260, 262
Manak, J. R. 240
Mancini, M. A. 39
Mandiyan, V. 137
Maniatis, T. 248
Mann, D. 200, 202, 214
Manzoli, F. A. 130, 138, 134, 132, 139, 137, 133, 135, 136
Manzoli, L. 130, 131, 132, 133, 136, 139
Marais, R. M. 240
Maraldi, N. M. 130, 134, 138
March, C. J. 270, 272
Marchisio, M. 132
Marck, C. 214
Marcus, S. 387
Margolin, K. 58
Mariani, B. D. 409
Maridor, G. 226, 234, 235, 238
Marini, G. 58
Marks, L. D. 411
Maroda, S. J. 58
Marolewski, A. 411
Marotta, M. 184
Marquez, V. E. 79
Marqusee, S. 269
Marshak, D. R. 238, 240
Marshall, C. H. 257
Marshall, J. 247
Marshall, M. S. 387
Marshall, R. D. 251
Marshan, P. R. 59
Martelli, A. M. 130, 131, 132, 133, 136, 139
Martial, J. A. 269
Martin, D. 58
Martin, D. S. 58, 59
Martin, D. W. 58
Martin, W. 307
Martin-Zanca, D. 249
Martino, G. 184
Masmoudi, A. 138
Massey, V. 100
Masters, J. N. 35, 36, 39
Matherly, L. H. 406, 407, 408
Mathieu, C. 238
Mathur, K. B. 269
Matsudaira, H. 184
Matsuka, T. 173, 185
Matsuno, T. 48
Matsuoka, N. 360
Matsushima, Y. 58
Matsushita, N. 165
Matsuzaki, T. 247
Matthews, C. K. 405
Matthews, D. A. 404, 405
Matthews, D. M. 402, 403, 405
Matwiyoff, N. A. 405
Maurer, F. 214
Maxfield, F. R. 275, 316
May, B. K. 161
May, W. S. 130
Maybaum, J. 110
Mayer, B. J. 269
Mayer, C. 29
Mayer, R. J. 58
Mayer-Jaekel, R. E. 214, 215, 218
Mazia, D. 184
Mazzei, G. J. 130, 138
Mazzoni, M. 132, 133, 134
Mazzotti, G. 130, 134, 138, 139
Mazzulla, S. 184
McBride, K. 137, 139
McCaw, B. K. 190
McCormick, F. 91
McCullough, J. 410
McDiarmid, S. V. 115
McDonough A. A. 184
McGee, E. 96
McGuigan, C. 240
McGuire, J. J. 407
McGuire, W. L. 119, 121
McIntosh, B. 42
McKay, D. B. 270
McKay, D. J. 91, 93
McKnight, G. S. 227
McManus, M. 161
Mearow, K. M. 42, 43
Mecke, D. 27, 28, 32, 35, 36, 38, 439, 40, 44
Medina, D. 258
Medrano, E. 14
Meese, K. 384
Meggio, F. 226
Megibow, A. 58
Meier, P. J. 373
Meijer, A. J. 27, 28, 30
Meisner, H. 226, 234, 240
Mejia, N. R. 412
Mekawa, H. U. 136
Mell, G. P. 402, 403
Menge, U. 358
Menssen, A. 307
Mercer, R. D. 399
Mercola, D. A. 388
Merlevede, W. 204, 214, 215, 216
Meyer, M. 260, 402, 409
Michaely, K. 226, 228, 229, 231
Michalopoulos, G. 29, 33, 34, 46, 50
Michel, A. 376
Miech, R. P. 95
Miksztal, A. R. 108, 112, 113
Milani, D. 132

Milburn, M. V. 270, 272
Mildvan, A. S. 286
Milenic, D. E. 121
Miles, E. W. 269
Mill, J. F. 42, 43
Miller, A. G. 162, 163
Miller, C. G. 356, 358, 361
Miller, J. R. 307
Miller, R. E. 27, 30
Milligan, D. L. 270, 272
Mills, S. D. 100, 107, 114
Miners, J. 161
Ming, L.-J. 347
Mini, E. 410
Minskami, S. 181
Mirkin, B. L. 92, 96, 103
Miscia, S. 133
Misra, D. K. 402, 409
Mitchell, B. S. 14, 20, 8
Mitchell, P. J. 251
Mitsuhashi, T. 183
Mittelman, A. 57
Mitzutani, A. 27
Miyajima, N. 119
Mobbs, J. D. 173, 183, 184
Mode, A. 39
Moe, G. R. 270, 272
Moertel, G. 58
Moffat, L. F. 386
Mohandas, T. 356, 358, 361, 164
Moloney, M. G. 335
Momand, J. 92
Momparler, R. L. 1, 8, 13, 14
Monte, M. J. 376
Montejano, Y. 414
Montfort, W. R. 411
Montgomery Jr, J. A. 405
Montisano, D. F. 164, 167
Mooney, R. A. 365
Moore, G. 164
Moorman, A. F. M. 27, 30, 31, 29, 33, 34, 41, 42, 43, 44
Moos, Jr, M. C. 365
Moran, M. F. 216
Moran, R. G. 59
Mordoh, J. 14
Morimoto, R. I. 382
Morini, P. 180
Moroson, B. A. 410
Morrell, L. 58
Morris, H. P. 91, 92, 96, 101, 103, 46
Morris, J. D. H. 257
Morris, N. R. 218
Moscat, J. 238
Mosse, H. 76
Moyer, J. D. 58
Muchnik, S. Ye. 191
Mueeler, B. M. 414
Muellener, D. 259
Mueller, C. G. F. 384
Muggia, F. M. 58
Mulholland, J. 137
Muller, C. D. 371, 376
Muller, P. 214
Müller, D. 385
Müller, M. 371, 372, 373, 374, 376
Müller, R. 385
Müller, W. E. G. 138
Muller-Eberhard, U. 40, 41
Multhauf, P. 58
Mumby, M. C. 215, 216
Munch-Petersen, B. 14
Münck, E. 346
Municio, M. M. 238
Murayama, K. 84
Musacchio, A. 269, 272, 307
Mylotte, K. M. 185

Na, G. 269
Nag, A. C. 39
Nagai, M. 72, 75, 84, 79, 80, 103, 109
Nagano, K. 272
Nagao, M. 203
Nagasaki, T. 412
Naiman, T. 227, 233, 234
Nakagawa, A. 359
Nakagawa, H. 93, 95, 96, 98, 100
Nakajima-Iijima, S. 233
Nakamura, H. 72, 75, 76, 77, 78, 81, 82, 103, 109
Nakano, K. 27
Nakielny, S. 211
Narayanaswami, V. 373
Narin, A. C. 199, 202, 204, 213, 214, 216
Naryzhnyi, S. N. 183
Natsumeda, Y. 1, 8, 71, 77, 103, 109, 115, 72, 81, 83, 84, 79, 80, 95, 96, 100
Naumova, G. M. 187
Nauta, R. 58, 59
Nayer, P. De 183, 184
Nebert, D. 163
Nebert, D. W. 159, 160
Nebert, W. 162
Neef, V. G. 403
Negishi, M. 162
Neitzel, J. J. 286
Nelson, M. T. 178
Nelson, P. H. 108, 112, 113
Nemtseva, L. S. 183
Neri, L. M. 130, 131, 132, 133, 136, 139
Neurath, H. 286
Newell, D. R. 59
Newman, E. 58

Nichol, C. A. 400, 401, 402, 409
Nichols, C. R. 79, 80
Nicklen, S. 248, 250
Nicotera, P. 138
Niedzwiecki, D. 58
Niermann, T. 269, 272, 275, 277
Nievers, M. 132, 136
Nigg, E. A. 226, 234, 235, 238
Nikodem, V. M. 183
Nikolskaya I. I. 183
Nilsson, N. ¿. 355, 358, 364, 365
Nilsson, T. 138
Ninomiya, H. 358, 359
Nishi, S. 227
Nishida, E. 216
Nishida, T. 373
Nishikawa, K. 272, 274, 275
Nishimoto, T. 216
Nishitani, H. 216
Nishizuka, Y. 257, 264, 382
Niu, X.-D. 202
Niwa, A. 159
Noble, M. 269, 290, 307
Noda, M. 247
Nolan, E. M. 35, 36, 39
Nomura, N. 119
Nord, L. D. 58
Nordenskjöld, A. 14, 17, 19, 1, 8
Nordheim, A. 265, 384, 385
Norman, C. 384
Norman, J. O. 138
Norskov, L. 358
North, A. C. T. 404, 410
Northrop, J. P. 164
Nose, K. 257
Novotny, A. 46, 50
Nowak, I. 227

O'Brien, P. J. 162
O'Connell, M. J. 58
O'Connor, B. M. 59
O'Dwyer, P. J. 59
O'Dwyer, P. O. 58
O'Neill, B. 373
O'Tousa, J. E. 202
Oberg, B. 14
Oborn, C. J. 258
Odujinrin, O. 58
Oefner, C. 404
Offringa, R. 386
Ogawara, H. 119
Ogden, R. C. 269
Ogg, D. 404, 410
Ognibene, A. 131, 132, 133, 139
Ohba, T. 58
Ohkura, H. 214, 215, 218
Ohno, S. 96
Ohtsubo, M. 216
Ojkmaa, K. 184
Okada, M. 93, 95, 96, 98, 100
Okayama, H. 247
Oken, M. M. 16
Okey, A. B. 159, 166
Oku, N. 258, 264
Okuda, H, 358, 359
Olah, E. 71, 79, 80
Oldfield, J. 59
Ole-Moi Yoi, O. K. 227
Olivecrona, T. 359
Olson, J. S. 100
Olsson, H. 357, 365
Omiecinski, C. J. 40, 41
Ong, A. 189
Ong, M. S. 165, 166
Ool, T. 272, 274, 275
Ooms, H. A. 376
Oppenheimer, J. H. 183
Orcutt, B. C. 275, 277, 279
Orrenius, S. 138
Orville, A. M. 346, 347
Osborn, M. J. 400, 401, 402
Osguthorpe, D. J. 270, 271, 275, 286
Osheroff, N. 226
Osterhout, J. J. 269
Otsuka, F. 382
Otsuka, H. 184
Otting, F. 403
Otto, G. 371, 372, 376, 377
Overduin, M. 269
Owaki, H. 386
Owens, I. S. 159
Owens, J. K. 14, 20
Owens, O. 163
Oxender, D. L. 269
Ozaki, T. 247, 251, 252
Ozon, R. 216

Padgett, R. A. 232
Padlan, E. A. 269
Padmanabha, R. 227
Padmanabham, S. 269
Pagliarini, C. 134
Pahlman, L. 58
Pall, M. L. 91
Pallen, C. J. 215
Palmer, G. 100
Pant, N. 269
Pantoliano, M. W. 121
Paques, E. P. 290
Pardee, A. B. 91, 101
Park, E. A. 183
Park, H. S. 61

Park, I.-K. 204, 206, 208
Park, J. 121
Park, S. 121
Park, W. 226, 234, 235
Parker, C. M. 108
Parker, P. J. 215
Parmelee, D. C. 286
Parrilla, R. 184
Pastan, I. 120, 121, 371, 409
Paterson, M. C. 190
Pathak, V. K. 91, 93, 95, 96, 100
Patkar, S. A. 360
Pato, M. D. 204, 212
Paul, A. R. 59
Paulik, E. 79, 80
Paull, K. D. 115
Paulson, K. E. 27, 30
Pauptit, R. 269, 290, 307
Pawelczak, K. 59
Pawson, T. 216
Payrastre, B. 132, 136
Pearch, H. L. 59
Pechatnikova, E. V. 174
Penmann, S. 136
Pepperkok, R. 226, 227, 228, 233, 238, 240
Perdew, G. H. 166
Perlmutter, D. H. 373
Peters, R. 241
Peterson, P. A. 307
Petrelli, N. 58
Petty, K. J. 183
Pfahl, M. 164, 238
Pfeifer, G. P. 384
Phillips, B. 382
Phillips, J. O. 58
Picking, W. D. 204
Piening, C. 226, 227, 231, 234
Pierce, J. H. 119
Piette, J. 384
Pillwein, K. 1, 8, 73, 84
Pines, J. 216
Pinna, L. A. 225, 226, 240
Pinna, L. A. 226
Piro, L. D. 15, 20, 22
Pitrelli, G. 184
Pliam, N. B. 183
Plocki, K. 376
Plunkett, W. 15, 22
Poellinger, L. 166
Poirier, M. 39, 48
Poland, A. 160, 165
Pollock, R. 384
Polverino, A. 387
Ponta, H. 259, 261, 381, 382, 384, 385, 387
Pool, C. W. 31
Poon, M. S. 58
Poore, G. A. 107, 114
Pope, L. E. 407, 412
Pope, S. 121
Popescu, N. C. 119
Portillo, R. M. 408
Posch, L. 262
Pöting, A. 381
Pourtier-Manzanedo, A. 371, 376
Prajda, N. 72, 75, 76, 77, 78, 81, 82
Pratt, A. J. 335
Presant, C. A. 91, 93, 95, 96, 100
Presnell, S. R. 270, 272
Press, M. F. 119, 121
Previati, M. 132, 133
Prevost, J. 382
Price, B. 257
Price, E. M. 408
Priest, D. G. 58
Primo, G. 376
Pringle, J. R. 214, 215, 218
Privalsky, M. L. 191
Prive, G. G. 270, 272
Probst, M. R. 165, 166
Proffitt, R. T. 91, 93, 95, 96, 100
Pryciak, P. M. 269
Prywes, R. 240, 384
Ptitsyn, O. B. 272
Pu, H. 42
Purohit, H. J. 42, 43
Purton, M. 269
Pyerin, W. 226, 228, 229, 231, 233, 236, 238, 240

Que, Jr, L. 347
Queener, S. W. 347

Rachev, R. R. 183
Radler-Pohl, A. 385, 386, 387, 391
Radparvar, S. 58
Radziech, D. 258
Rahmsdorf, H. J. 385, 386, 387, 391, 259, 381, 382, 384
Rahmsdorf, J. 259, 261
Rahmsdorf, U. 259, 261
Rai, K. R. 16
Raina, P. N. 35, 36
Raistrick, H. 107
Rana, R. 133
Randall, C. R. 347
Randall, R. J. 3
Randle, P. J. 200, 202, 214
Rapp, U. 385, 386, 387, 391
Rasch, S. 265
Rasumovskaya, N. I. 184

Rats, H. 238
Ray, L. B. 216
Raynor, R. L. 262
Reardon, M. A. 71, 72, 81, 83, 84
Reddy, P. 233
Reddy, R. 58
Reed, J. C. 231
Reed, L. J. 202
Rees, D. C. 269, 290, 298
Reichard, P. 14, 58
Reichen, J. 28, 33, 41
Reilly, E. 233
Reiman, E. M. 356
Reiser, J. 115
Reisfeld, R. A. 414
Reisz-Porszasz, S. 165, 166
Remondelli, P. 382
Renard, A. 269
Renaux, B. S. 91, 93
Renz, M. 385
Resh, M. D. 269
Resink, T. J. 356
Reutter, W. 371, 372, 373, 374
Revesz, L. 58
Reyes, H. 164, 167, 165
Reynolds, K. R. 14
Rhee, S. G. 132, 133, 136, 137
Rhim, J. S. 121
Rhoden, K. J. 175
Ricci, D. 132, 133, 134
Richards, W. G. 275
Richardson, D. C. 269
Richardson, J. S. 269
Richman, S. 58
Rideout, J. L. 1, 8, 14
Ridgeway, T. 269
Rieger, R. 202
Rihs, H. P. 241
Rijksen, G. 408
Rimoldi, D. 247
Ringheim, G. E. 286
Ringold, G. M. 164
Rinzel, S. M. 59
Riordan, G. S. 120
Rios, C. B. 269
Rizzoli, R. 130, 134, 138
Roach, P. J. 199, 205, 206, 211, 212
Robbins, D. J. 386
Roberts, D. 406
Roberts, G. C. K. 403
Roberts, J. 115
Roberts, T. M. 257
Robertson, S. C. 269
Robin, P. 263
Robins, R. K. 79
Robitzki, A. 228, 229, 230, 236
Robson, B. 271, 272, 274, 291, 294, 298
Rodbard, D. 58
Rodriguez Viciana, P. 387
Roeder, R. G. 384
Roeske, R. W. 205, 211, 212
Rogers, M. P. 363
Rogue, P. 138
Román, I. D. 376
Romanini, A. 58
Romanov, V. P. 183
Romisch, J. 290
Ronai, Z. A. 381
Rose, P. A. 14
Rosebrough, N. J. 3
Roselli, M. 121
Rosen, F. 35, 36
Rosen, M. K. 269, 291, 307
Rosen, O. M. 365
Rosenbauer, H. 240
Rosenberg, R. N. 57, 60
Rosenberg, S. A. 84
Rosenthal, J. T. 115
Rosenzweig, B. 233
Rosette, C. 388, 389
Ross, D. A. 21
Ross, D. J. 107
Ross, J. 42
Ross, R. 362
Rossi, F. 181
Rost, B. 271, 274, 275, 280, 285, 287, 288, 294, 296, 297
Rothberg, K. G. 408
Rothenberg, K. G. 409
Rotin, D. 137
Rottier, R. 385
Rottmann, M. 138
Roy, A. K. 39
Rozek, D. 384
Rubin, C. S. 226, 227, 233
Rudakov, N. P. 187
Ruddle, F. H. 14
Rudinger, A. 185
Ruhnau-Brich, B. 307
Runswick, M. 384
Rupp, R. 165
Russell, D. W. 386
Russell, L. D. 58
Russell, R. B. 269, 272, 290, 331
Russell, V. P. 180
Rustum, M. 65
Rustum, Y. M. 57, 60, 58
Ryffel, B. 371

Sabatelli, P. 130, 132, 134, 137
Saccoccia, P. A. 95
Sachs, L. 159

Sachsenmaier, C. 385, 386, 387, 391, 381, 382, 389
Sadee, W. 110
Safa, A. R. 371
Sager, R. 247
Saheki, T. 27
Sahyoun, N. 138
Saito, T. 119
Saito, Y. 359, 361, 360
Sakai, H. 216
Sakharov, V. N. 390
Sakiyama, S. 247, 251, 252
Salmons, B. 259
Salvo, J. Di 206, 208, 209
Salyamon, L. S. 191
Sambrook, J. 248
Sampson, S. R. 184
Samson, S. M. 347
Samuels, H. H. 183
Samuels, L. L. 411
Sander, C. 271, 274, 275, 280, 285, 287, 288, 294, 296, 297, 307
Sander, D. A. 91
Sander, F. 164, 167, 162
Sander, M. 138
Sanders, J. M. 408
Sanger, F. 248, 250
Sanghvi, A. 376
Sano, K. 257, 264
Santi, D. V. 411
Santi, P. 133
Santi, S. 134
Sanz, L. 238
Saraste, M. 269, 272, 307
Sarkar, F. H. 39
Sarnecki, C. 257
Sarno, S. 215
Sarre, T. F. 129, 130, 138
Sartorelli, A. C. 80
Sasaki, K. 203
Sasaki, M. S. 190
Sase, M. 27
Sassenfeld, H. 270, 272
Sassone-Corsi, P. 263
Sassone-Corsi, R. 258
Sasvari-Székely, M. 14
Sato, E. 27
Sato, J. K. 412
Saunders, P. P. 15, 22
Saurer, S. 119
Savaraj, N. 58
Saven, A. 20, 22
Sawyer, R. 58, 59
Sblano, C. 180
Schafer, R. 247
Schäfer, M. 28, 33, 29
Schareck, W. 39
Schaub, T. 371, 372, 373
Scheja, L. 39
Schelling, D. L. 357
Schenker, S. 28
Scheraga, H. A. 275, 316
Schetter, L. K. 58
Schiffer, C. A. 16
Schimke, R. T. 409
Schinella, R. 58
Schlessinger, J. 119, 137, 383
Schlom, J. 121
Schmid, F. A. 411
Schmid, H. 27, 30
Schmitt, C. A. 184
Schmoll, H. 58
Schnable, P. S. 307
Schnapp, A. 240
Schneider, R. 271, 274, 275, 280, 285, 287, 288, 294, 296, 297
Schoenenberger, C. A. 258
Schofield, C. J. 347
Schofield, J. 346
Schöls, L. 28, 29, 30, 32, 33
Schönthal, A. 259, 261, 381, 384, 385
Schornagel, J. H. 408
Schorpp, M. 381
Schotz, M. C. 356, 358, 361
Schrag, J. D. 358
Schreiber, K.-L. 30, 32, 44
Schreiber, S. L. 269, 291, 307
Schrenk, D. 45
Schreyer, A. 371, 372, 373, 374
Schrode, W. 29, 30, 35, 39, 40, 44
Schröder, H. C. 138
Schröter, H. 384, 385
Schulz, G. E. 272
Schulz, W. 29
Schulze-Gahmen, U. 411
Schütz, G. 259
Schwager, C. 227, 228, 230, 233
Schwartz, H. L. 183
Schwartz, R. M. 275, 277, 279
Schwarz, M. 227
Scott, J. 200, 202, 214
Scott, W. G. 270, 272
Scuetz, E. G. 40, 41
Seaver, S. S. 58
Sebolt, J. 21
Sebrell Jr, W. H. 399
Seegmiller, J. E. 92, 96, 103
Segal, J. 185
Segatto, O. 119
Seger, D. R. 399
Seguin, C. 382
Seidel-Dugan, C. 269, 291, 307
Seiler, S. 232
Seino, M. 227

Seino, S. 227
Seipel, K. 227
Self, A. J. 257
Semba, K. 119, 121
Sentenac, A. 214
Senter, P. D. 414
Sergeyev, P. V. 180, 181
Serra, D. 200
Serrero, G. 39
Setlow, R. B. 190
Settleman, J. 387
Seydel, U. 137
Shainberg, A. 185
Shalnov, M. I. 185
Shane, B. 58, 407
Shannon, J. M. 39
Sharif, H. 191
Sharonov, B. P. 174
Sharp, A. M. 358, 360
Shaw, G. 42
Shaw, P. E. 265, 384, 385
Shen, Y.-Q. 307
Shenolikar, S. 199, 202, 204, 213, 214, 216
Sherley, J. L. 91, 92, 93, 95, 101, 102
Shewach, D. S. 14, 20
Shi, D. 121
Shibley, I. A. 2, 3, 4, 5, 8
Shih, C. 59, 259
Shima, H. 203
Shimono, H. 13, 14
Shimura, K. 93, 95, 96, 98, 100
Shin, T. B. 269, 291, 307
Shirai, K. 359, 361
Shiraki, H. 93, 95, 96, 98, 100
Shively, J. E. 356, 358, 361
Shober, R. 95
Shoji, D. 286
Shoji, M. 262
Shoji, S. 286
Shouji, M. 373
Shows, T. 233
Shum, K. Y. 411
Shuster, J. 58, 129
Sibanda, B. L. 287
Sibley, C. H. 164
Sidransky, D. 91
Sies, H. 27, 28, 44, 373
Silber, R. 402, 409
Silberman, H. 59
Silverman, J. A. 371
Silverman, L. 269
Simmerman, H. K. B. 178
Simon, M.-T. 42
Simon, M. I. 91, 137
Simoncini, E. 58
Sinelshchikova, T. A. 192
Singh, G. 59
Singhal, R. L. 72, 81, 82
Sippel, C. J. 373
Sirma, H. 48, 49, 50, 39, 45
Sirotnak, F. M. 406, 407, 411
Sizenko, S. P. 189
Skold, O. 58
Skroch, J. 211
Slamon, D. J. 119, 121
Slater, T. F. 189
Slice, L. W. 286
Sloane, D. A. 184
Slocum, H. K. 58
Smaling, M. M. 42
Small, C. A. 355, 363
Smeal, T. 385, 387, 388, 138, 240
Smith, B. P. 190
Smith, G. M. 360
Smith, H. H. 164
Smith, J. 27
Smith, J. M. 399
Smith Jr, D. D. 27
Smith, K. A. 270, 272
Smith, P. A. 58
Smith, S. L. 402, 403, 405
Smith, T. J. 185
Sneddon, A. A. 214, 218
Snee, J. 355, 364
Snell, K. 73
Snyder, F. F. 91, 93
Sobrero, A. 410
Söderhall, S. 173, 184, 185
Soeters, P. B. 28, 30
Sogawa, K. 163, 165
Sokoloski, J. A. 80
Sola, M. 203, 204, 212
Sollinger, H. W. 115
Solodkov, A. P. 180
Solomon, M. J. 216
Soltoff, S. 247, 251, 129
Somlyo, A. P. 212
Somlyo, A. V. 212
Sommercorn, J. 226, 240, 251
Song, S. V. 120
Sonne, J. C. 399
Sorger, P. K. 382
Sorrell, S. 371
Sowadski, J. M. 269, 270, 285, 290
Sparkes, R. 164
Sparkes, R. S. 356, 358, 361
Spasokoukotskaja, T. 14, 17, 18, 19, 20, 21
Spears, C. P. 58
Spector, D. L. 238, 240
Spena, A. 184
Spencer, D. B. 399
Spevak, W. 211

Spiegelman, S. 58, 59
Spyrou, G. 14
Squarzoni, S. 130, 132, 134, 137, 138
Sridhar, K. 58
Srinivasan, S. 270, 272
Srivastava, P. 79
Stablein, D. M. 58
Stalmans, W. 199, 202, 204, 213, 214, 216
Stammers, D. K. 404, 410
Stampfer, M. R. 164
Stapleton, A. E. 214, 215, 218
Stark, G. R. 58
Stark, M. 214
Stark, M. J. R. 218
Starke, G. R. 58, 60
Staub, M. 14
Stec, J. 138
Steele, F. R. 202
Steffen, A. 390
Stein, B. 381, 382, 386, 387, 390
Stein, G. S. 91, 101
Stein, J. L. 91, 101
Steinberg, D. 57, 60, 362, 364
Stenbäck, F. 48, 49, 50
Stephanov, V. E. 173, 183, 185
Sterling, K. 180, 183, 184
Sternberg, M. J. E. 275, 286, 287, 307
Stetsenko, I. P. 185
Stewart, A. A. 357
Stewart, J. 269
Stieger, B. 373
Stiera, E. 411
Stokstad, E. L. R. 399
Stolfi, R. 58
Stone, B. G. 376
Stone, E. M. 213, 218
Stone, S. R. 214
Staålfors, P. 209, 355, 356, 358, 364, 365
Strait, K. 183
Strathmann, M. P. 91
Street, A. J. 203, 208
Ström, A. 39
Stroud, R. M. 411
Stuart, S. G. 119, 121
Stunnenberg, H. G. 240
Sturgill, T. W. 216
Styles, C. A. 218
Suchy, F. J. 373
Sudo, C. 119
Sugar, J. 80
Sugimoto, C. 227
Sugimoto, Y. 247
Sugimura, T. 203, 216
Sugino, H. 13, 14
Suh, P. 132
Suh, P. G. 132
Sunkel, C. E. 214, 215, 218
Sunwoo, J. 207
Surerus, K. K. 346
Surks, M. J. 183
Suzuki, K. 96, 382
Svenson, K. L. 356, 358, 361
Sviderskaya, E. V. 178
Swain, S. M. 57, 60
Sweeney, M. J. 107, 108, 114
Swiderek, K. M. 204, 209, 211
Swindells, M. B. 270, 290, 294, 295, 305
Swyryd, E. A. 58
Sylvester, R. F. 399
Sylvia, V. L. 138
Szekeres, T. 81, 103, 109
Szelenyi, J. 80
Szondy, S. 71, 72, 81, 83

Taguchi, O. 39
Taira, K. 405
Takai, A. 202
Takai, Y. 258, 264
Takebe, H. 190
Takeda, E. 21
Takenawa, T. 257
Takeshige, K. 181
Takeuchi-Suzuki, E. 387
Takio, K. 226, 227, 231, 234
Talbot, N. 247
Taljanidisz, M. 14
Tamai, I. 371
Tamiya-Koizumi, K. 136
Tanaka, T. 28, 30
Tang, P. M. 204, 209, 211
Taniguchi, H. 231
Taniki, T. 72, 75, 84
Tanneberger, S. 59
Tapscott, S. 165
Tata, J. R. 183
Tatchell, K. 211
Tatsumi, M. 190
Tattersall, M. H. N. 58
Taylor, E. C. 59
Taylor, G. A. 59, 411
Taylor, S. S. 269, 270, 285, 290
Taylor, W. R. 275, 286
Te Kortschot, A. 28, 30
Teitz, T. 227
Temple, C. 405
Ten Eyck, L. 269, 270, 285, 290
Ten Vorde, G. H. J. 27, 31
Tepliz, R. 190
Teraoka, H. 13, 14
Thaler, F. 46, 50
Thayer, M. 165
Thiebaut, F. 371

Thim, L. 358, 360
Thomas, G. 216
Thomas, S. M. 257
Thompson-Jaeger, S. 211
Thoreau, E. 273, 292
Thorgeirsson, S. S. 159, 160, 371
Thornton, J. M. 270, 290, 294, 295, 305
Throng, J. 202
Tian, E. 58
Timchenko, O. I. 185, 187, 188
Timmermant, H. 173, 185
Titani, K. 286
Tjian, R. 251
Todd, G. C. 59
Tokumo, K. 39, 48
Tollet, P. 39
Tolley, S. 358
Tomasetto, C. 247
Tomlanovich, S. B. 115
Tonks, N. K. 205, 208
Topol, L. Z. 173, 183, 184
Torrance, P. M. 58
Toumadje, A. 269
Toyoshima, K. 119, 121
Traugh, J. A. 225, 226, 240
Treisman, R. 384
Tricot, G. J. 71, 79, 80
Trouche, T. 263
Trowsdale, J. 408
True, A. E. 347
Tsien, R. Y. 129
Tsujita, T. 358, 359
Tsukitani, Y. 202
Tsuruo, T. 371
Tuazon, P. T. 225, 226, 240
Tubiana, M. 190, 191
Tuliparo, G. 133
Turkenburg, J. P. 358, 360
Turner, D. 165
Turner, R. W. 107, 114, 100
Turner, W. B. 107, 114, 100
Tuttle, J. V. 1, 8, 14
Twentyman, P. R. 371
Twose, P. A. 110, 114
Tyalor, S. S. 286
Tyler, G. 130
Tyrrell, R. M. 381

Überall, F. 260, 262
Udani, M. 376
Udove, J. 119, 121
Uhler, M. D. 227
Ullman, B. 14, 20, 58, 93
Ullrich, A. 119, 121, 227
Ultsch, M. 269
Umemura, T. 39, 48
Usatenko, M. S. 184

Vale, K. 59
Van Aelst, L. 387
Van Andel, R. E. 27, 31
Van Bergen En Henegouwen, P. M. P. 132, 136
Van Cott, A. C. 79
Van Dam, H. 385
Van de Zande, L. 27, 42
Van Den Berg, S. 381
Van Den Bogaert, A. J. W. 42
Van Den Hoff, M. J. B. 42
Van Der Bliek, A. 371
Van Der Eb, A. J. 385, 386
Van Eynde, A. 200, 204, 213
Van Genderen, I. L. 134, 137
Van Gurp, J. R. 164
Van Meer, G. 134, 137
Van Noorden, C. J. F. 27
Van Oorschot, D. A. J. 42
Van Thiel, D. H. 376
Van Zyl, W. 214
Vandenheede, J. R. 204
Vanderbilt, C. A. 386
Vanetti, M. 381, 382
Varesio, L. 258
Vaynson, A. C. 191
Vella, L. M. 166
Venema, H. 43
Vereschangina, G. V. 191
Verkleij, A. J. 132, 136
Verma, I. M. 385, 258
Vermeulen, J. L. M. 27, 30, 31
Vermeulen, V. P. E. 173, 185
Vilenchik, M. M. 189
Villa Moruzzi, E. 204
Villacorte, D. G. 91, 93, 95, 96, 100
Vincedon, G. 138
Vitols, K. S. 407, 408, 412, 414
Vladimirov, Yu. A. 180, 181
Vogelstein, B. 91
Vogler, W. R. 262
Voit, R. 240
Volkova, T. M. 187, 189
Volz, K. W. 404, 410
Voorhout, W. F. 134, 137
Voss, H. 226, 227, 228, 233, 236
Votrin, I. I. 173, 183, 184

Wade, R. D. 286
Wagenaar, G. T. M. 31
Wainer, I. W. 58
Waksman, G. 269

Walczak, J. 59
Waldleworth, J. M. 59
Waldman, S. 58
Walker, D. H. 217
Walsh, K. A. 226, 227, 231, 234
Walter, G. 215
Walton, K. M. 199, 200
Wan, K. M. 136
Wang, C. C. 107
Wang, L. 14, 17, 18, 19
Wang, Y. 205, 211, 212
Warne, P. H. 387
Warty, V. 376
Washburn, T. 202
Wasylyk, B. 258, 263
Wasylyk, C. 258, 263
Watanabe, K. 58
Watanabe, N. 165
Wate-Field, M. D. 119
Waterfield, M. D. 215, 227
Watras, J. 173
Watson, A. J. 163, 166
Watt, F. M. 40
Watt, P. 211
Weaker, A. B. 175, 177
Weaver, D. W. 58
Weber, G. 72, 75, 76, 77, 78, 81, 82, 1, 8, 103, 109, 115, 21, 71, 73, 79, 84, 91, 92, 96, 101
Wegmann, M. A. 226, 227, 228, 233
Wegmann, R. J. 226, 227, 228, 233
Wegner, H. 39
Wehr, K. 227
Weinberg, R. A. 119, 259
Weiner, L. M. 59
Weinstein, G. D. 410
Weinstein, I. B. 381
Weintraub, H. 165
Weir-Brown, K. I. 163
Weitman, S. D. 408
Weitz, S. 227, 228, 234
Wek, S. A. 365, 366
Welch, A. D. 400, 401
Wenger, R. 138
Wentrup, C. 274
Werner, M. 214
Werner, S. C. 183, 187, 191
Westerhof, G. R. 408
Whiteley, H. R. 400
Whiteley, J. M. 403
Whiteside, S. T. 129
Whitlock, J. P. 159, 162, 163
Whitlow, M. 120
Whittle, N. 227
Widmer, H. 269
Widnell, C. C. 183
Wieand, H. S. 58
Wierenga, R. 269, 290, 307
Wiesenfeld, M. 58
Wigler, M. 387
Wilcox, W. 269
Wild, M. 233
Wilkstrom, A.-C. 166
William, D. 184, 185
Williams, G. M. 28, 30, 33, 39, 48, 49, 50, 58
Williams, R. H. 107, 114
Williams, S. S. 76
Willingham, M. C. 371, 409
Willis, A. C. 335
Willis, R. C. 92, 96, 103
Wilson, I. A. 411
Wilson, J. H. P. 28, 30
Wilson, R. H. 27, 31, 42
Wilson, T. 42
Wilson, T. M. 59
Wilson, Y. 96
Winkler, F. K. 358, 360, 404
Winter, M. A. 59
Winterbourn, C. C. 178
Wirkner, U. 226, 227, 228, 233
Wissler, R. W. 362
Wittschieber, E. 269
Wodinsky, I. 406
Wolf, M. 138
Wolf, S. 307
Wolff, J. A. 399
Wolff, S. 183
Wolff, S. P. 175, 178
Wolfman, A. 257
Wong, A. 58
Wong, B. S. 35, 36
Wong, N. C. 183
Wong, S. G. 119, 121
Wood, K. W. 257
Wood, S. L. 356, 357
Woodcock, V. 42
Woodgett, J. R. 138, 386
Woolley, P. V. 58
Worzalla, J. R. 59
Wright, D. 80
Wu, C. 31, 32, 35
Wu, D. 137
Wu, S. 358
Wu, T. T. 272
Wynn, J. J. 180
Wynne, J. 240

Xin, Y.-R. 164
Xuong, N. H. 269, 270, 285, 290

Yagi, Y. 27
Yamada, Y. 115, 71, 79, 80, 307

Yamaji, Y. 71, 79, 96
Yamamoto, K. R. 164
Yamamoto, T. 119, 121
Yamano, H. 213, 218
Yamashita, K. 216
Yan, J. 202
Yanagida, M. 213, 218
Yanagishita, T. 173, 185
Yang, S.-D. 204
Yang-Feng, T. L. 227, 233, 234
Yaniv, M. 384
Yarmonenko, S. P. 191
Yasuda, H. 216
Yasumoto, K. 216
Yeaman, S. J. 355, 364, 365, 363
Yeh, J. 270, 272
Yeh, W.-K. 307
Yeh, Y. A. 81
Yellowlees, D. 204
Yeshchenko, N. D. 183
Yin, M.-B. 58, 65
Yokota, J. 119
Yomma, Y. 257
Yonemoto, W. M. 286
Yoshida, S. 359, 361, 136
Yoshida, T. 58
Yoshida, Y. 138
Yoshioka, T. 134, 137
Young, A. P. 42
Young, C. W. 59
Yu, H. 269, 291, 307
Yu, H. T. 291
Yu, I. J. 238, 240
Yuferov, V. 403
Zakrezewski, S. F. 402, 409
Zang, Y. 347
Zaniboni, A. 58
Zanoni, L. 247
Zantema, A. 385, 386
Zarow, C. 58
Zasukhina, G. D. 192
Zellenka, U. 211
Zevely, E. M. 407
Zhang, S. 121
Zhang, X. 387
Zhang, Z.-G. 57, 60, 58, 65
Zhao, S.-Y. 14
Zhau, H. E. 121
Zhen, E. 386
Zhen, W. 79, 80, 84
Zhen, Y. S. 72, 75, 84
Zheng, J. 269, 270, 285, 290
Zheng, K. 227, 233, 234
Zhestyanikov, V. D. 182, 187
Zhou, D. 119
Zhu, Z. 137
Zielinska, Z. M. 58
Zimmermann, J. 227, 228, 230, 233
Zini, N. 130, 132, 134, 137, 139
Zmudzka, B. Z. 381
Zolnierowicz, S. 214, 215, 218
Zonneveld, D. 36, 44
Zozak, M. 250
Zurawski Jr, V. R. 408
Zvelebil, M. J. J. M. 275, 307
Zwelling, L. A. 61, 62, 79
Zwiller, J. 138
Zydowsky, L. D. 291

SUBJECT INDEX

Acanthifolicin inhibition of protein phosphatases 202
N-2-Acetylaminofluorene (AAF) on GS distribution in liver 46
Acivicin
  dipyridamole synergism 84, 86
  non-targeted action 83, 85
  on bone marrow cellularity 82, 83
  on glutamine-utilizing enzymes 82
  on TdR kinase 83
  targeted action 85, 86
Actin filaments, anti-PIC γ1 antibody and 135, 136, 140
Acute lymphocytic leukemia, MTX treatment 399
Acyl CoA: cholesterol acyl transferase (ACAT) in cholesterol ester cycle 363, 364
Adenine phosphoribosyltransferase (APRT, EC 2.4.2.7)
  cycloheximide on 77, 84
  $t_{1/2}$ 84
Adenosine kinase (EC 2.7.1.20)
  activities in L1210 cell lines 7
  deficient L1210 cell line 2, 6–10
  substrate specificity 1, 8, 10
Adipose tissue, regulation of HSL in 357, 365
  action of perilipin 365
Aflatoxin B_1 (AfB_1) hepatocarcinogenesis by 49
Ah receptor *see* Dioxin (Ah) receptor
Alcohol dehydrogenase
  internal α-helices assignments 286
  surface residue assignments 281
Allopurinol-tiazofurin chemotherapy 79, 86
Alpha helices assignment in protein structures 285–287, 331–346
Alpha tocopherol antioxidant activity 181, 182
Amethopterin *see* Methotrexate
Amino acid conservation in proteins 277, 278
  evolutionary distance on substitution 279, 280
Aminopterin introduction into chemotherapy 399
Anthocyanidin synthase (subfamily A2p) *see also* HAFE family of proteins
  evolutionary tree 308, 309
  secondary structure
    assignment 339
    helical wheel used to assign 319
    parses 318
  structure prediction, tabulation of multiple alignment 310–315
  superfamily common feature 306, 307
Antifolate
  ICI-D1694 structure 59
  TS inhibitors advantages 59, 60
Antigen processing
  by cathepsin B 145–157
  by cathepsin E 145
Antigenic peptides
  binding to MHC class II 151–153
  stimulation of splenocytes 148
  stimulation of T cells 149
Antioxidant action 175
  at different stages of tumorigenesis 189, 190
  dithiothreitol 177, 178
  methionine 177, 178
  thyroid hormones 179
AraA (adenine arabinoside, 1-β-D-arabinosyladenine)
  on L1210 cell growth 5, 7, 8, 10
  phosphorylation 9
    by dCK 14, 15
    by dGK 14, 15
AraC (cytosine arabinoside, 1-β-D-arabinosylcytosine)
  on L1210 cell growth 3, 4, 9
  phosphorylation
    by dCK 14, 15
    in L1210 cells 4
    kinase for 8
AraG (guanine arabinoside)
  on L1210 cell growth 3, 4, 9
  phosphorylation
    by dGK 15, 19
    kinase for 8
AraHx phosphorylation by dGK 15
AraT phosphorylation by TK2 15, 19
ARNT protein
  analysis 165
  basic helix–loop–helix motif 165
  heterodimeric DNA-binding complex 166, 168
  in Ah receptor model 166

Aryl hydrocarbon hydroxylase (AHH)
activities in Hepa-1 recessive mutants 162, 163
activity as monitor for P4501A1 159
induction by polycyclic aromatic hydrocarbons 159
Aspartate aminotransferase surface residue assignments 281
Aspartate transcarbamylase (ACTase, EC 2.1.3.2) and PALA 57, 58
Atherogenesis
characterization 362
HSL role in 355
foam cell development 362
LDC plasma concentrations 362
ATP
-dependent transport 371–378
export carriers
in liver vesicles 372–378
in mastocytoma cells 373, 375, 378
labeling *in vivo* by [^{14}C] hypoxanthine 111, 115
levels in rat heart, MPAS on 111
levels in rat spleen, MPAS on 110, 111
ATPase, Ca^{2+} (EC 3.6.1.3)
assay 174
gene, thyroxine effect on 184
HOC1 on 176–178, 192
TH on 184, 185, 188
AZT (3′-azido-2′,3′-deoxythymidine)
phosphorylation by TK1 14, 15, 19
synergistic action in salvage pathway 86

Benzo(a)pyrene (BP) induction of resistant (AHH-deficient) mutants of Hepa-1 cells 161
Beta strands assignment in protein structure 285, 286, 331–346
Bile salt export carrier in liver canalicular membrane 376, 377
Biotin-MTX
formula 407
in isolation of folate transporter 407, 408
Bryostatin-1
inhibition of PKCα 264
on transcriptional activation 265

Ca^{2+} homeostasis, TH on 184, 188
nuclear and cytoplasmic aspects 185
possible role in repair 187
Ca^{2+} transport in SR
HOC1 on 176
protection from 177–179, 192
measurement 174

Calyculin A inhibition of protein phosphatases 202
Cancer chemotherapy *see* Chemotherapy
Carbamoyl-phosphate synthase 1 (CPSI, EC 6.3.4.16) distribution in liver 27, 31
Carbon tetrachloride injury to liver 29, 45, 48
Carcinogenesis
antioxidant effects 189, 190
influence of thyroid hormones 189, 192
p53 function and 92
relevance of P4501A1-dependent AHH activity 160
role of IMPD 104
significance of *ARNT* gene 167
Casein kinase II (CKII, ATP: phosphotransferase, EC 2.7.1.37)
alternative names 225
autophosphorylation 226, 228, 229
cloning procedures 228, 229
cytoplasmic requirement at early G_1 and G_1/S transition phases 242
functions 226
gene isolation 229
genes, chromosomal localization 227
holoenzyme, tissue-derived and reconstituted 231, 236
human cell culture 228
hybridization *in situ* 229
immunological techniques 230
in mitogenic signal transmission 226, 238
mitogenic stimulation 226, 228, 242
monomeric CKs 225
nuclear/cytoplasmic ratio 237, 238
nuclear protein substrates 240
nuclear requirement in different phases of cycle 239, 240, 242
phosphorylation of ATP-Mg-dependent phosphatase 204, 205
range of functions controlled 241
structure 226
substrates 225
subunit α
accession numbers of nucleotide sequence data 225
activation of β 237
amino acid sequence 226, 230
chromosomal location 233, 234, 241
gene
sequence 227, 241
structures 232, 233
transcription 234
cis acting element 236
regulation 235, 236
in reconstituted holoenzyme 231
overexpression on β 237

(pseudo)gene 227, 232, 241
accession numbers of nucleotide sequence data 225
regulation 235, 236
size 233
subunit α′
amino acid sequence 226, 230
chromosomal location 234
gene transcription 234
regulation 235, 236
in reconstituted holoenzyme 231, 241
passive role 237
subunit β
accession numbers of nucleotide sequence data 225
amino acid sequence 226, 230
antibodies
cytoplasmic injection 238–240, 242
nuclear injection 238–240
on mitogenesis 228, 238–240
autophosphorylation 226, 231, 241
chromosomal location 234, 241
gene
sequence 227, 241
structures 232, 233
transcription 234, 235
cis-acting element 236
initiation by α 237
promoter activity 236, 242
regulation 235, 236
in reconstituted holoenzyme 231
size 233
subunits 226, 231
evolutionary conservation 226, 230, 233
transcription control 227
transfection 229, 237
Cathepsin B
active site homology with MHC class II 152
antibody on T cell proliferative response 149, 150
cystatin family and 153–156
homology with HLA-DR7 155, 156
inhibitor CA-074 145
on responses to hepatitis B 146–148
on responses to rabies 149–151
inhibitor E-64 145
on responses to hepatitis B 146–148
on responses to rabies 149–151
inhibitors action on antigen proteolysis 150, 156
invariant (Ii) chain association 153, 156
limited proteolysis 151, 152
processing of exogenous antigens 145, 151–153, 156
Cell
cycle, phase dependence on CKII requirements 238–240
immortalization, IMPD activity and 91–104
membrane enzyme systems, antioxidant protection 174, 175
signalling
nuclear transduction system 134, 137
PIC isoform partitioning and 133
regulatory events 129
Chemotherapy
aminopterin 399
CdA on human malignancies 15, 22, 23
enzyme-pattern-targeted 84–87
FUra/LV 58
FUra/PALA 59
FUra resistance 57
ICI-D1694
in vitro 60
in vivo 65
IMPDH target 115
MPA considerations 108, 114–116
MTX (methotrexate) 397–415
acquired resistance 409
analogs 410–412
optimization 412–414
OLX-209 121–127
tiazofurin 79
Chloramphenicol acetyltransferase (CAT)
assay 259
fos construct transcriptional activation 261, 262, 265
TK construct transcriptional activation 262, 263, 266
2-Chloro-2′-deoxyadenosine (CdA)
cytotoxicity 15
on L1210 cell growth 7, 8, 10
phosphorylation
by dCK 14, 15, 19
correlation with enzyme content 20
by dGK 14, 15
in L1210 cells 4
treatment of CCL and HCL patients 22–24
2-Chloro-2′-fluoroadenine arabinoside on L1210 cell growth 7, 8, 10
Cholesterol esters
HSL activity on 355
uptake by macrophages 362
normal cycle in 363
Choriocarcinoma, MTX treatment 399
Chronic granulocytic leukemia, tiazofurin chemotherapy 79
Chronic lymphocytic leukemia (CLL)
cell dCK content 20

cell sample analysis 16
treatment with CdA 15, 16, 22
phosphorylation in responders and non-responders 22–24
Cirrhosis
CCl_4 induced 48
GS levels in 50
Clinical oncology, OLX-209, potential applications 121, 122
Collagenase
family (hemorrhagic metalloproteases)
internal α-helix prediction 287
tabulated comparison of secondary structure predictions 300–303
merits of different methods 304, 305
gene transcription, UV induced 390
Cycloheximide effect on
3924A cells 77
APRT 77, 84
CdR kinase 84
GMP reductase 77, 84
GMP synthase 77, 84
GPRT 77, 84
IMP dehydrogenase 77, 84
rat bone marrow 84
TdR kinase 77, 84
dTMP synthase 77, 84
Cyclosporin A (CsA)
analog PSC 833 *see* PSC 833
inhibition of
ATP-dependent export pumps 371
daunorubicin transport 373, 374
LTC_4 transport 373–376
taurocholate transport 373–375
modifications to produce PSC 833 376
on hepatic taurocholate accumulation 377
side effects of immunosuppressive therapy 376
Cystatin family
cathepsin B and 153–156
homology with invariant chain 153–157
Cysteine protease inhibitors 145
CA-074 suppression of immune response to
hepatitis B 146–148
rabies 148–151
E-64 suppression of immune response to hepatitis B 146–148
rabies 148–151
Cytochrome P4501A1
CYP1A1 structural gene 162
transfection 164
expression by AHH activity 159
expression, genetic analysis of regulation 159–168
expression instability in H4IIEe3 cells 161

Daunorubicin, APT-dependent transport
inhibition by CsA 373, 374
inhibition by PSC 833 373, 374
measurement 372
Deacetoxycephalosporin C synthase (expandase family Exp)
evolutionary tree 308, 309
secondary structure of Exp family
assignment 332–334
consensus 342, 343
parses 316, 317
structure prediction
active sites 347, 348
tabulation of multiple alignment 310–315
superfamily common features 306, 307
Degradation rates of purine and pyrimidine enzymes 76, 77
Deoxyadenosine
kinase activities in L1210 cell lines 7
on L1210 cell growth 5
Deoxycytidine kinase (cytosolic, dCK, EC 2.7.1.74)
absence in resistant cells 14
assay 17
deficient L1210 cell line 2
deoxynucleoside salvage in human cells 13, 14
expression in human cells and tissues 19, 20
immunoquantitation 17–20
levels in tumor and normal tissues 21
lymphoid cell expression 14
multiple substrate binding domains 8, 9
properties 15
substrate specificity 1, 5, 14, 15, 23
$t_{1/2}$ 76, 84
Deoxycytidine phosphorylation in L1210 cells 4
nucleosides on 5
Deoxyguanosine kinase (mitochondrial, dGK, EC 2.7.1.113)
deoxynucleoside salvage in human cells 14
expression in human cells and tissues 19
properties 15
substrate specificity 14, 15, 23
Deoxyguanosine
on L1210 cell growth 3, 4
phosphorylation in L1210 cells 4
nucleosides on 5
phosphorylation, kinase for 8
-resistant L1210 cells (dGuo-R) 2–6, 9

2′-Deoxy-2′-methyleneadenosine (MdAdo)
on L1210 cell growth 6–8, 10
2′-Deoxy-2′-methylenecytidine
on L1210 cell growth 6–8, 10
phosphorylation in L1210 cells 10
2′-Deoxy-2′-methylguanosine
on L1210 cell growth 6–8
phosphorylation in L1210 cell lines 10
Deoxynucleoside kinases
human, properties 13–24
phosphate donors 14
substrates 8–10
Dexamethasone (DEX)
induction of c-*fos* 261
on GS 36–38
2,6-Diaminopurine chemotherapeutic actions 398
2,4-Diaminopyrimidines chemotherapeutic actions 398
5,10-Dideazatetrahydrofolate
antifolate 411
structure 412
Diethylnitrosamine (DEN)
hepatocarcinogenesis by 49
on GS distribution in liver 46
2′,3′-Dideoxycytidine (ddC)
phosphorylation by dCK 14, 15
2′,2′-Difluoro-2′-deoxycytidine on L1210 cell growth 6, 10
Dihydrofolate reductase (DHFR, EC 1.5.1.3)
active site 404
complex with MTX 403–405
elevation after MTX treatment 409, 414
identification of enzyme 401, 402
in thymidylate synthesis cycle 402
inhibition by diamino compounds 398
isolation 403
preferential binding to MTX 405
purification 403
structure 403
target for MTX 72, 78, 399–402, 414
Dimethyl sulfoxide (DMSO) induction of differentiation in Friend cells 138, 139
Dioxin (Ah) receptor
action of xenobiotic responsive element 163
activity in Hepa-1 mutants 163
basic helix–loop–helix motif 165, 168
comparison with ARNT protein 165, 167, 168
in induction of P450-dependent AHH activity 160
model of mechanism of action 166
protein sequence comparison with ARNT 165
role of heterodimeric DNA-binding complex 166, 168
Dipyridamole synergistic action in cytotoxicity 84, 86
Dithiothreitol (DTT) antioxidant action 177, 178
DNA
lesions UV-induced 390
repair
effect of thyroxine 185, 186
in prereplicative systems 187, 189
impairment and carcinogenesis 190
oxidative phosphorylation requirement 184
sense/antisense oligonucleotides on CKII inhibition 226, 228, 237
single-strand break (SSB)
assay 61
correlation with growth inhibition 64
synthesis
IGF-I trigger 138
inhibition by CKIIβ antibodies 238, 239
role of PKC 138, 139
cDNA 3Y1 cells 248
library construction 248
NO3
as transcription regulator 251
protein 1 amino acid sequence 250
sequence analysis 249, 250
λZAPII library 249
Drugs, anticancer, design strategy 71

Enzyme *see also* individual enzymes
-monoclonal antibody conjugate to target MTX 413, 414
-pattern-targeted chemotherapy 57, 84–87
Epidermal growth factor (EGF) inhibition of UV response 388
Epinephrine
on GS in hepatocytes 36, 37
role in glycogen metabolism 210, 216
erbB-2 (oncoprotein)
binding regions in OLX-209 120
binding to e23 antibody chain 120
expression in various human tumor cells 124
overexpression in human cancers 121
overexpression in malignant transformation 119
target for OLX-209 118, 119
Escherichia coli DHFR complex with MTX 403–405
Esterase activity of HSL 358, 363, 366
tryptic digestion on 359
Estradiol on GS in hepatocytes 36, 37

10-Ethyl-10-deaza-aminopterin (Edatrexate, MTX analog)
clinical trials 411
structure 410
Ethylene biosynthesis proteins (family Erp) *see also* HAFE family of proteins
evolutionary tree 308, 309
secondary structure
assignment 339
parses 318
structure prediction, tabulation of multiple alignment 310–315
superfamily common features 306, 307
Expandase family *see* Deacetoxycephalosporin C synthase
Extracellular matrix
-cell interaction model for GS expression 44, 45
on GS activity in cultured hepatocytes 40, 41, 50

Flavanone hydroxylases (subfamily Fop, EC 1.14.11.9) *see also* HAFE family of proteins
evolutionary tree 308, 309
secondary structure
assignment 339
helical wheel used to assign 319
parses 318
structure prediction tabulation of multiple alignment 310–315
superfamily common features 306, 307
FLT phosphorylation by TK1 15
Fluorescein-MTX
formula 407
visualization of DHFR cellular levels 409
visualization of membrane protein 407
2-Fluoroadenine arabinoside (FaraA)
on L1210 cell growth 5, 7, 8
phosphorylation 9, 10
possible use with araA 10
2-Fluorodeoxyadenosine (FdAdo) on L1210 cell growth 5
5-Fluoro-2′-deoxyuridine (FdUrd)
metabolic pathways 57
phosphorylation by TK1 14, 15
phosphorylation by TK2 14, 15
5-Fluorouracil (5-FU)
AZT synergism 86
chemotherapy with LV 58
chemotherapy with PALA 59
dose–response studies 79
incorporation into RNA 58, 59
metabolic pathways 57
non-targeted action 83, 85
on cellularity 80
on dTMP synthase 78–80
on rat bone marrow enzymes 78
on TdR kinase 78–80
targeted action 85, 86
time sequence studies 80
Foam cell
development role of HSL in 362, 363
HSL inhibitor protein in 364, 365
Folate
metabolism
dTMP production and 73
ICI-D1694 on 64, 65
transport proteins
micromolar system 406–408
nanomolar system 406, 408, 409
Folic acid (pteroylglutamic acid) structure comparison with antifolates 398, 399
Folylpolyglutamate synthetase (FPGS, EC 6.3.2.17)
decreased activity in MTX resistance 409
in folate transport system 406, 407
5-Formyltetrahydrofolic acid (folinic acid, leucovorin)
in one-carbon metabolism 400, 401
isolation 399
rescue in MTX therapy 412, 413
structure 400
substrate in folate transporter 406
10-Formyltetrahydrofolic acid
in one-carbon metabolism 400, 401
structure 400
c-*fos*
AP-1 (FAP) site in *ras*-mediated *fos* induction 262, 263
-CAT constructs 251, 261, 265
gene
expression 258
Raf induction 388
transcription, UVC induced 382, 388
UV responsive element 384
induction by
dexamethasone 261
Ha-*ras* 261
PKC dependence 262–264
suppression by BM41440 262, 263
TPA 261
c-Fos protein response to
phorbol ester 385, 388
Raf 388
UV 385, 388

Gene
amplification induced by MTX treatment 409
ARNT, Ah receptor nuclear translocator 164

analysis of ARNT protein 165
basic helix–loop–helix motif 165
significance in carcinogenesis 167
cloning, Hepa-1 mutants 164, 167
CYP1A1, P4501A1 structural 162
expression
growth factor induced 384
GS in liver 28, 42–46
inhibition by Ras and Src negative mutations 251, 388
of NO3
in human lung and lung tumor 252
in transformed 3Y1 cells 251, 254
in 3Y1 cells 249
tissue distribution and 252
vector construct 252
p53 *see* p53 antioncogene
tumor suppressor, characterization 247–254
Genetic homeostasis, role of TH 183
Glucagon on GS in hepatocytes 36, 37
Glucocorticoids on GS in hepatocytes 35–37
Glutamine synthetase (GS, EC 6.3.1.2)
appearance in neoplastic cells 49, 50
as possible diagnostic marker 50, 51
in cirrhosis 50
in human hepatocellular carcinoma 50
appearance in preneoplastic hepatocytes 48
CCl_4 treatment on 32, 33
developmental aspects of regulation 30
distribution in liver
carcinogens on 46
relative mean width parameter 46–48
expression in transplanted hepatocytes 33–35
gene in liver
functional characterization 42, 43
regulation of heterogeneous expression 43
cell–cell interactions model 44, 45
compartment/differentiation hypothesis 45, 46
extinction/induction model 44, 45
gradient model 43
pathology on 28
hormonal influence on cellular distribution 36–39
hormonal regulation of activity 34–38
immunocytochemistry 29
immunohistochemical localization 27
in hepatocarcinogenesis 28
in rat parenchyma, sexual differences 39
induction by co-cultivation of hepatocytes 39, 40
influence of extracellular matrix 40, 41
influence of soluble factors 40
partial hepatectomy on 31
mRNA 27
role in liver 27, 28
$t_{1/2}$ 46
Glycinamide ribonucleotide transformylase (EC 2.1.2.2) inhibition by antifolates 411
Glycogen metabolism
epinephrine in 210, 216
insulin effect 210, 211, 216
regulation of glycogen SR-associated phosphatase 210
regulatory role of phosphatase inhibitor-2 208
Glycogen phosphorylase (EC 2.4.1.1) in glycogen metabolism model 210
Glycogen/SR-associated phosphatase
constituents of 201, 209
$G(R_{GL})$ subunit 209
homology with yeast gene product 211
possible dephosphorylation by PP2A 212
in vivo substrates 209
regulatory subunit synergistic phosphorylation 205, 206
structure and regulation model 210
tissue distribution 209
Glycogen synthase (GS, EC 2.4.1.11)
in glycogen metabolism model 210
in growth factor signal transduction 216
synergistic phosphorylation by GSK-3 and CKII 206
Glycogen synthase kinase-3 (GSK-3)
phosphorylation and activation of ATP-Mg-dependent phosphatases 204, 205
PP1 isoform subunit 203, 204
synergistic phosphorylation of different substrates 205, 206
GMP reductase (EC 1.6.6.8)
cycloheximide on 77, 84
$t_{1/2}$ 84
GMP synthase (EC 6.3.5.2)
cycloheximide on 77, 84
$t_{1/2}$ 84
Growth factor *see also* Epidermal growth factor
induced gene expression 384
receptors
inhibition by suramin 389

role of protein phosphatase 2A 216
UV activation 389
signal transduction
cascade diagram 217
protein phosphatase 2A in 216
Growth hormone on GS in hepatocytes 35–39
GTP
labeling by [^{14}C] hypoxanthine 110, 111, 115
levels
in cultured glioma cells MPA on 114
in rat heart MPAS on 109, 110
in rat spleen MPAS on 109–111
Guanine nucleotides
metabolism and p53 expression 92
regulatory role in cell growth 91, 104
Guanine phosphoribosyltransferase (GPRT, EC 2.4.2.8)
cycloheximide on 77, 84
$t_{1/2}$ 76, 84
tiazofurin on 79

HAFE family of proteins, secondary structure
assignment 339–342
helical wheels 320–324
consensus 344–346
parsing 344–346
Hairy cell leukemia (HCL)
CdA treatment 15, 16, 22
cell, dCK content 20
cell sample analysis 16
Hemorrhagic metalloproteases *see* Collagenases
Hepatitis B vaccine
antigenic peptides 148
immune response 146
inhibition by cathepsin B inhibitors 146–148
Hepatocarcinogenesis
glutamine metabolism and 46
mechanisms for different agents 48, 49
significance of GS 50
Hepatocytes
co-cultivation with RL-ET-14 cells 39
soluble factors produced 40
culture 29
GS$^+$
after CCl_4 treatment 32, 33
after partial hepatectomy 31, 32
phenotype stability 30, 33, 50
fetal, GS distribution in 30
hormonal effects on GS 34–39
transplanted, GS expression in 33–35
transplantation into fat pads 29
HMG-CoA reductase (EC 1.1.1.34) in lipid metabolism 357
Hormone-sensitive lipase (HSL, EC 3.1.1.3)
activity loss in cholesterol ester-loaded cells 364, 366
catalytic activities 355
esterase
interfacial activation 360, 361
tryptic digestion on 358, 359
lipase
substrate specificity 358
tryptic digestion on 358, 359
catalytic domain sequence 360–362
dephosphorylation 356
relative activities of PP1, PP2A and PP2C 357
domain structure 358–362
functional domains 362, 366
in foam cell development in atherogenesis 362–366
in macrophages 355, 363
inhibitor protein 364, 366
lipid-binding domain 360, 362
neutral hydrolysis of cholesterol esters 355, 363, 366
phosphorylation sites 362
basal (site 2) 356, 361, 362
mutually exclusive characteristic 356, 366
regulatory (site 1) 356, 361
rat-human sequence comparison 361
regulator, translocation mechanism 365
relation to lipase gene family 358
specificity 355, 366
Human
adrenal cancer SW13 cells *erb*B-2 expression 124
breast cancer
cells
BT-474 *erb*B-2 expression 124
MCF-7 *erb*B-2 expression 124
MDA-MB-231 *erb*B-2 expression 124
SK-Br-3 *erb*B-2 expression 124
*erb*B-2 overexpression in 119, 121, 122
possible OLX-209 therapy 122
cancers
associated with DNA repair deficiency 190
*erb*B-2 overexpression in 121
protooncogene identification 119
casein kinase II *see* Casein kinase II
CCRF-CEM malignant lymphoblast cells
deoxynucleoside kinase activities 19

mutant cell lines 16, 17
use in assaying dCK antibody specificity 20
colon carcinoma, dCK levels comparison with normal tissue 21, 23
EBV-transformed B cells, p53 stabilization by X-rays 382
epidermoid tumor A431 cells *erb*B-2 expression 124
F9 teratocarcinoma stem cells, UV gene transcription 382
gastric cancer N87 cell xenografts OLX-209 assay 124, 125
HCT-8 carcinoma cells
cell quantitation 61
growth inhibition
assay 61
by ICI-D1694 in nude mice 65
by ICI-D1694 *in vitro* 62
DNA SSB and 64
leucovorin on 63–65
TdR on 62, 64, 65
HeLa tk$^-$ cells
c-Fos protein, UV and phorbol ester on 385
UV and phorbol ester induced signal transduction 386–388
hepatocellular carcinomas, GS activities in 50, 51
HL-60 cells, tiazofurin induced differentiation 80
leukemia cells (*see also* CLL and HCL)
deoxynucleoside kinase activities 19
variation in dCK content 20
liver tumor
HepG2 cells *erb*B-2 expression 124
Huhl cells *erb*B-2 expression 124
lung
and lung tumors, NO3 gene expression 252, 253
Calu-3 cells, *erb*B-2 expression 124
fibroblast IMR 90 cells, CKII distribution studies 238–240
lymphomas CdA treatment 15
neutrophils
activation by PMA 181
HOC1 generation 175
respiratory burst inhibition by TH 181, 192
ROS from 175, 181
normal
leukocytes deoxynucleoside kinase activities 19, 20, 23
solid tissue deoxynucleoside kinase activities 19, 21, 23
ovarian cancer
*erb*B-2 overexpression in 122
possible OLX-209 therapy 122
solid tumor tissue deoxynucleoside kinase activities 19, 21, 23
stomach cancer,
*erb*B-2 overexpression in 122
N87 cells, *erb*B-2 expression 124
expression 124
T cell clone, proliferation response procedure 146
to rabies vaccine 148
suppression 148–150
vulva cancer KB cells, *erb*B-2 expression 124
Hydroxyurea (HU) site of chemotherapeutic action 57
Hyoscyamine 6β-hydroxylase (subfamily Hd) *see also* HAFE family of proteins
evolutionary tree 308, 309
secondary structure
assignment 339
parses 318
structure prediction, tabulation of multiple alignment 310–315
superfamily common features 306, 307
Hyperthyroidism
carcinogenesis association 189
increase of antioxidant enzymes in 180
Hypochlorite (HOC1)
cause of neutrophil luminescence 182
formation by activated neutrophils 175
on SR membranes 175, 176
antioxidant protection 177, 178
phosphorylation protection 178
Hypoxanthine on MTX effects 73

ICI-D1694 antifolate
growth inhibition of HCT-8 cells, schedule dependency 62–65
on membrane transport 64, 65
site of action, cytotoxicity
DNA SSB correlation 64
leucovorin reversal 63
TdR reversal 62
structure 59
Immune response suppression by
cathepsin B inhibitors 146, 147
Mofetil 108, 115
Immunosuppressive therapy, cyclosporins side effects 376–378
Inosine-5′-monophosphate (IMP) endogenous levels in cell-free extracts 97
Inosine-5′-monophosphate dehydrogenase (IMPDH, EC 1.1.1.205)
activity
correlation with cell renewal capacity 103, 104

diagnostic tests 98
effect of cell lysis method 98
effect of detergent 96
elevation in tumor cells 91
in different growth states 92, 101, 102
in various tissue extracts 96, 103
kinetics in exponentially growing cells 99
serum deprivation on 101, 103
tissue and protein content relationships 97, 99
chemotherapeutic target 115
cycloheximide on 77, 84
in C127 cells 95, 99
in cell growth control 103
increase on immortalization 103
inhibition by MPA 99, 100, 107, 114
K_i values 114
possible complex formation 114
relationship with p53 expression 91, 92, 95
role in carcinogenesis 104
spectrophotometric assay 94–97, 104
substrate inhibition by NAD 99, 101
$t_{1/2}$ 84
tiazofurin on 79, 81
trichomonas foetus source 107
Insulin
in HSL control 355, 356
on GS in hepatocytes 35–37
Insulin-like growth factor-I (IGF-I) stimulation of 3T3 cells 130, 133, 138–140
Insulin-stimulated protein kinase (ISPK) phosphorylation role in glycogen metabolism 210, 211, 216
Interleukin-6 (IL-6) on GS in hepatocytes 36, 37
Invariant (Ii) chain peptide
association with cathepsin B 153, 156
complex with MHC class II 153
homology with cystatin 153–155
Ips family *see* Isopenicillin N synthases
Isopenicillin N synthases (family Ips) *see also* HAFE family of proteins
IPNS superfamily secondary structural model 306–348
active site assignments 346–348
common features 306, 307
evolutionary tree 308, 309
IPs family
assignment 334–339
helical wheels for 324–331
consensus 343–346
parses 317
protein B 317
tabulation of multiple alignment 310–315

c-*jun* gene transcription, UVC induced 382, 388
c-*Jun* protein response to
phorbol ester 386
Ras 388
UV 385

Lactate dehydrogenase (EC 1.1.1.27) surface residue assignments 281
Leucovorin (LV) *see also* 5-Formyltetrahydrofolic acid
modulation of 5-FU therapy 58, 65
reversal of ICI-D1694 cytotoxicity 62
Leukotriene C_4 (LTC_4), ATP-dependent transport
inhibition by CSA 373–376
inhibition by PSC 833 373–376
measurement 372
Lipases *see also* Hormone sensitive lipase
gene family separation of HSL from 358, 362
interfacial activation 360
pancreatic
domains of 358
homology to fungal 358
proteolysis on activities 359
Liver
development in several species, GS zonation 30, 31
GS gene, regulation of expression 42–46
Low density lipoprotein (LDL) association with atherogenesis 362

Macrophages
cholesterol ester overload in atheroma 362
scavenger receptor for modified LDLs 363
Mercapto-2-methoxy-methyl-propyl-1-phosphocholine (Ilmofosine, BM41440) inhibition of PKC 261, 262, 266
5,10-Methenyltetrahydrofolic acid
in one-carbon metabolism 400, 401, 411
structure 400
Methionine synthase (EC 2.1.1.13) target in folate-dependent systems 412
Methotrexate (MTX, amethopterin)
analogs
D1694 411, 412
5,10-dideazatetrahydrofolate 411, 412
edatrexate 410
pyrimethamine 410, 411
trimethoprim 410, 411

trimetrexate 410
-antibody conjugates 413, 414
antipurine action 72, 73
antipyrimidine action 73, 75
AZT synergism 86
blocking of routes to tetrahydrofolate 413
-DHFR complex 403, 404
binding, preference over folates 405, 414
interaction site 405
discovery 397–399
dose–response studies 75
high-dose therapy, leucovorin rescue 412, 413
non-targeted action 75, 78, 83, 85
on cellularity 75, 76
on DHFR 72, 78
on rat bone marrow 72, 75, 76
on TdR kinase activity 75, 76
on dTMP synthase activity 75, 76
resistance 402, 403, 409, 410, 414
DHFR reduced affinity 409
FPGS reduced activity 409
gene amplification 409, 410
transport protein reduced affinity 409
use of analogs 410
structure 398
target identification 399–402
targeted action 72, 78, 85, 86
time-sequence studies 76
transport
micromolar system 406
polyglutamylation 407
substrate translocation protein 407, 408
with 5-FU 413
4-Methyl-2,6-diisobutyl phenol (ionol) antioxidant activity 181, 182, 192
5,10-Methylenetetrahydrofolate in one-carbon metabolism 401, 411
5,10-Methylenetetrahydrofolate dehydrogenase (EC 1.5.1.5) target in folate-dependent systems 411
6-Methylmercaptopurine riboside on L1210 cell growth 6, 7, 10
5-Methyltetrahydrofolate
in one-carbon metabolism 401, 412
substrate in folate transporter 406
MHC class II
binding to antigenic peptides 151–153
cathepsin B and 145
complex with invariant chain 153
Microcystins inhibition of protein phosphatases 202
Mitogen signal transmission, role of CKII 226, 238, 239, 242
Mitogen-activated protein (MAP) kinase
in UV and phorbol ester signal transduction 386
Ras-Raf induction 388
translocation to nucleus 129
MoFe nitrogenase secondary structure predictions 298, 299, 304
Mofetil (RS-61443) *see* Mycophenolic acid morpholinoethyl ester
Monoclonal antibodies (MoAbs)
anti-PIC isoforms 132, 135, 138
anti-PIP_2 134
Mouse
BALB/C
immunization 145
responses to hepatitis B vaccine 146, 147
responses to rabies vaccine 150, 151
splenocyte proliferation assay 146
splenocyte proliferation cathepsin B inhibitors on 147, 148, 150, 151
C127 cells
G_0 state 101
IMPDH activity in extracts 101, 102
TK activity in extracts 101, 102
immortalization changes 103
IMPDH activity in extracts 95, 98, 100
p53 protein in 95
serum deprivation on 93, 101
CD-1, OLX-209 hepatic toxicity 126, 127
10(1) cells
absence of p53 gene product 95
G_0 state 101
IMPDH activity in extracts 101, 102
TK activity in extracts 101, 102
immortalization changes 103
IMPDH activity in extracts 95
serum deprivation on 93, 101
Friend erythroleukemia cells, clone 707
culture 130
differentiation 133, 134, 138–140
PIC isoforms location 138
polyphosphoinositide synthesis in isolated nuclei 133
hepatoma cell line Hepa-1
BP^r (AHH-deficient) mutants
Arnt gene mapping 163, 164
biochemical analysis 162–164
Cypla-1 mRNA levels 162, 163
genetic analysis 162
isolation 161, 168
origin of dominant 163, 167
transfection of A^- with rat *CYP1A1* 164
transfection of B and D genes 167

transfection of C⁻ with human *ARNT* 164
xenobiotic responsive element action 163
suitability for AHH induction studies 160
L1210 cell lines
dGuo-R 2, 10
growth
adenine nucleosides on 5, 9
nucleoside analogs on 6
nucleosides on 4
nucleoside kinase activities in 4, 9
ED2 2, 10
adenosine kinase activities in 7, 9
deoxyadenosine activities in 7
growth, nucleoside analogs on 6–8
folate transport proteins 406
isolation using biotin-MTX 407, 408
MTX elevation of DHFR 409
wild type
growth
adenine nucleosides on 5
nucleoside analogs on 5
nucleosides on 4
nucleoside kinase activities in 4
mammary epithelial HC-11 cells
culture 258, 259
subcellular distribution of PKC isozymes 263, 264
transfection procedure 259
induction of c-*fos* 260, 261
elements required for 262, 263, 266
mastocytoma cells L138 C-10a LTD_4 export carrier 372, 375, 377
Swiss 3T3 cells
culture 130
immunoblotting analysis 136
PICs location in 132, 133, 135, 136, 138, 140
stimulation by IGF-I 130, 133, 138, 140
Multidrug resistance (MDR) mdr 1 gene product characterization 371
Mutations in proteins, probability of occurrence at adjacent residues 277–279
myc oncogene down regulation by tiazofurin 80, 81
Mycophenolic acid (MPA)
absence of effect on G-protein-mediated activities 114
antimicrobial activity 107
antiproliferative activity 107
antipsoriatic activity 108
antitumor activity 108, 114
conversion to glucuronide 107, 108
chemotherapeutic significance 108, 115
disodium salt (MPAS) 108
on ATP metabolism 110, 111
on GTP metabolism 109–113
inhibition of IMPDH 99, 100, 107, 114
morpholinoethyl ester (MPAME, Mofetil, RS-61443)
immunosuppressive activity 108, 116
improved availability in monkey studies 112
in rheumatoid arthritis 115
on GTP metabolism 112
on neuroendocrine responses 114
pharmacodynamics, comparison with MPAS and MPAME 112–115
structure 107
Myeloperoxidase formation of HOC1 175
Myoglobin surface residue assignments 281

Neomycin-resistance gene
in pMEXneo vector 249
in pSV2neo vector 259, 261
Norepinephrine on GS in hepatocytes 37
Nuclear
matrix
phospholipids in 134, 137
PIC β1 in 136, 140
PKC association 138
PLA_2 association 136
preparation 131
signal transduction system 129–140
in different cell types 132, 133, 135
responses to agonists 138
role of matrix 139
Nucleoside kinases *see also* individual nucleosides
deficient L1210 cell lines 1–10
activity assays 3
activity levels compared 4
in 5-fluoropyrimidine pathways 57

Okadaic acid
cell permeation by 202
inhibition of protein phosphatases 202, 216
OLX-209 protein
anti-tumor activity in xenografts 124, 125
design details 119–121
design principles 118
e23 sequence 120
inhibition of protein synthesis *in vitro* 123, 124

safety evaluation 125–127
Oncogenes down-regulation by tiazofurin 80
2-Oxoglutarate-dependent oxidases (EC 1.14.11) superfamily common feature 306, 307, 317

p21^{ras} activation of PKC 257
p53 antioncogene
induction at low doses of Xrays 383
relationship with IMPDH 91, 95
$t_{1/2}$, X-ray irradiation prolongation 383, 391
target for mutation 92
Perilipin
adipocyte specificity 366
role in HSL regulation 365
P-glycoproteins
binding by CsA derivatives 371
export pump function 371
inhibition by cyclosporins 377
multidrug resistance modulation 371
Phorbol esters induced
AP-1-dependent promoter constructs 387
changes in transcription rate 282
post-transcriptional changes 385, 386
signal transduction, hypothetical scheme 390
4β-Phorbol 12-myristate 13-acetate (PMA) activation of neutrophils 181
Phosphatase inhibitor-2 (I-2)
-CS1 complex 207, 208
functional role 207
modifications on activity 207
on type 1 protein phosphatases 201
regulation 204, 208
Phosphatidylinositol-3-phosphate (PI_3) kinase in signal transduction 129, 130
Phosphatidylinositol-4-phosphate (PIP)
hydrolysis effects 137
synthesis in isolated nuclei 133
Phosphatidylinositol-4,5-phosphate (PIP_2)
hydrolysis effects 137
monoclonal antibody, EM immunocytochemistry 134
synthesis in isolated nuclei 133
Phosphoinositidase C (PIC)
isoforms
identification in various cell types 132
immunocytochemistry 130–132
localization in subcellular fractions 136
location in various cell types 132, 133, 140
partitioning of 135
reversible binding 137
targets of 137
type β1
activation by G proteins 137
activation in nucleus 130, 140
nuclear location 133, 135, 136, 138
type γ1
actin filament association 135–137
cytoplasmic location in 3T3 cells 133, 135, 136
in Friend cell nucleus 138, 140
in signal transduction 129, 130
type δ1 cytoplasmic location in PC12 cells 133
Phospholamban, muscle protein, phosphorylation protections in SR membranes 178
Phospholipase A_2 (PLA_2, EC 3.1.1.4)
association with nuclear matrix 136
gold labeling 132, 134
N- (Phosphonoacetyl)-L-aspartate (PALA)
chemotherapy with 5-FU 59
site of chemotherapeutic action 57
Phosphorylase kinase PHK
subunits substrates for protein phosphatases 200
in glycogen metabolism model 210
in growth factor signal transduction 217
Plastocyanin surface residue assignments 281
p-nitrophenyl butyrate (PNPB), HSL esterase activity against 358
interfacial activation 360, 361
trypsin insensitivity 358, 359
Polycyclic aromatic hydrocarbons (PAHs)
binding by dioxin receptor 160
induction of AHH 159
association with toxicity in cultured cells 159
by benzo(a)pyrene 161
correlation with carcinogenesis in mice 160
Polypeptide chain volume 276
Polyphosphoinositides
hydrolysis in isolated nuclei 133
intranuclear localization 134, 139
effects of PICs breakdown products 137
synthesis in isolated nuclei 133
Protein kinase A (PKA) translocation to nucleus 129, 130
Protein kinase C (PKC, EC 2.7.1.37)
activation in *ras*-transformed cells 257
analysis 260
inhibition by BM41440 261, 262
intranuclear sites 137, 138
isozymes
expression 263

α inhibition by bryostatin-1 264
requirement for H-*ras* induction of c-*fos* 264, 266
in signal transduction 257
nuclear targets 138
requirement for *ras* induction of *fos* 262, 263
translocation to nucleus 129, 130, 138
Protein kinase CKII *see* Casein kinase II
AMP-activated Protein kinase
phosphorylation of HSL site 2 356, 363, 366
cAMP-dependent Protein kinase
in glycogen/SR-associated phosphatase action 210–212
phosphorylation of HSL site 1 356, 364, 366
regulatory subunit (CREB) synergistic phosphorylation 205, 206
Protein kinases
cascade, protein phosphatases role 216, 217
diversity compared with protein phosphatases 199, 202, 218
role in UV response 387, 388, 391
structure prediction
alignment of segment 275
probability of a gap 276
assignment of interior positions 284
α-helices 285–287, 299, 304, 305
assignment of surface residues 280
using concurrent variation 283
β-strands 285, 286, 299, 304, 305
bona fide 285
comparison of Zurich and Heidelberg assignments 295–298
consensus model limitations in superfamily 287
secondary structure information 277
turn assignment by adjacent conserved/variable residues 278, 279
Protein phosphatases (PPs, EC 3.1.3.16)
broad classification 200
inhibition by okadaic acid 357, 363
range of known types 199
regulatory subunits, significance 200
serine/threonine
classification table 201
specificity 202, 203
regulatory role of subunits 203, 204
type 1 (PP1)
ATP-Mg-dependence 203, 204
catalytic subunit isoforms 201–203, 205, 208, 356
evolutionary conservation 202, 219
forms of 201, 203
glycogen/SR and 203, 204
myosin and 203
heat stable inhibitors 200
inhibitor-1 activation 200
inhibitor-2 structure and function 204–209
myosin and nuclear associated chromatin association 213
NIPPP1 nuclear inhibitor 200, 204, 213
subunits 212
non-protein inhibitors 202
on HSL site 2 357
physiological role 215, 219
cell cycle regulation 216–218
glycogen metabolism 216, 217
preferred substrate 200
regulatory subunit 201, 203
type 2A (polycation-stimulated)
catalytic subunit 201, 202
A isoforms 214, 215
B isoforms 213–215
substrate specificities 214
combinatorial association of subunits 213, 219
evolutionary conservation 202, 219
inhibitors 200, 202
on HSL 357
physiological role 215
cell cycle regulation 216–218
growth factor receptor 216
maturation inhibition 216
signal transduction pathways 216, 217
structure–function relationships 214, 215
trimeric forms 213, 214
type 2B
Ca^{2+} requirements 200
catalytic subunit 201, 202
regulatory subunit 201
type 2C
catalytic subunit 201, 202
Mg^{2+} requirement 200
on HSL 357
regulatory subunit 201
Proteins
half-life prolongation by UV irradiation 382, 383
oxidation by ROS 176
protection by phosphorylation 177–179
structure predictions
bona fide 290, 295–298, 303, 306, 307
consensus models, limitations 287, 288

features of Zurich E.T.H. method 305, 306, 348
historical development 269–275
bacterial aspartate receptor 270
bona fide 270, 272
conformational instabilities 274
interleukins 270
protein kinase superfamily 270
research paradigms 1986 271, 272, 274
secondary structure inaccuracies 272, 273
tertiary structure importance 272
three state per residue score 271, 273, 286, 291
molecular evolution 270–280
classical critique of contemporary paradigm 294
effect of residue conservation on adjacent residues 277, 278
evolutionary distance (PAM units) 275
amino acid substitution 279–281
point accepted mutations (PAM) 275
probability of alignment gap 276
neural network 270, 292, 293, 348
secondary
α-helix 285–287
assignment 331–342
break from gaps in multiple alignment 277
collagenases, comparison 300–304
consensus 342–346
parsing heuristics 316
refinements 288–290
SH3 domain 290–294
superfamily multiple alignment 293
surface residues 280
using naive and revised heuristics 281, 282
tertiary 280–284
consensus model 289
development of interior heuristics 283, 284
development of surface heuristics 282
evolutionary divergence quantitation 281
tryptophan synthase 275, 277
turns 279
synthesis inhibition
by OLX-209 123
by PE 120, 121
PSC 833 (cyclosporin A analog)
inhibition of
daunorubicin transport 373–375
LTC_4 transport 373–376
taurocholate transport 373–375
lack of immunosuppressive properties 376
on hepatic taurocholate accumulation 377
Pseudomonas exotoxin (PE)
cell killing 119
mechanism 120, 121
cytotoxicity limitation 121
regions incorporated into OLX-209 120
Psoriasis
MPA treatment 108
MTX treatment 399
absence of resistance development 410
Purine biosynthesis
de novo pathway enzymes 72, 73
salvage pathway enzymes 73, 86
Pyrazofurin on L1210 cell growth 6, 7, 10
Pyrimethamine
diffusion entry into cells 411
folate antagonist 410
structure 411
Pyrimidine biosynthesis
de novo pathway enzymes 72
salvage pathway enzymes 73, 86
Pyrogenal activation of neutrophils 181, 182

Rabies vaccine
antigenic peptides 149
immune response 148
inhibition by cathepsin B inhibitors 148–151
Radiotherapy, normal tissue protection by thyroid hormones 190–193
Raf-1 dominant negative mutant on UV response 387, 391
Ras
dominant negative mutant on UV response 387, 388, 391
signalling from plasma to nucleus 387, 388
c-Ki-*ras* oncogene down regulation by tiazofurin 80, 81
Ha-*ras*
gene 259
expression, mitogenic response 257
induction of c-*fos* 261
cell-type specific differences 263, 264
PKC-dependence 258, 262, 263
transfection of HC-11 cells 260–265
Rat
bone marrow
acivicin on 84
cycloheximide on 84

5-FU on 78–80
MTX on 72, 75, 76
tiazofurin on 81
fibroblast
v-Ha-*ras*-transformed 3Y1 cells, NO3 expression in 251
v-*src*-transformed SR-3Y1 cells
absence of NO3 expression 251
culture 248
growth assay 249
transfection with NO3 cDNA 249, 253
3Y1 cells
culture 248
DNA sequencing 248
cDNA
library 248, 249
NO3 249–251, 254
Northern analysis 248
heart
ATP, MPAS on 111
GTP, MPAS on 109, 110
hepatocytes, thyroxin-stimulated repair of X-ray damage 186, 192, 193
animal age effect 188
optimum treatment time 187
hepatoma 3924A, cycloheximide measurement of enzyme $t_{1/2}$s 76, 77
hepatoma H4IIec3 cell line
AHH induction in 160
instability of BP-resistant clones 161
pheochromocytoma PC12 cells, PICs location in 133
RL-ET-14 cells co-cultivation with hepatocytes 29, 39
soluble factors produced 40
SD strain in OLX-209 toxicity test 126
spleen
ATP, MPAS on 110, 111
GTP, MPAS on 109, 110
strains, response differences of GS after partial hepatectomy 32
Reactive oxygen species (ROS)
cellular targets 188
dithiothreitol scavenging 177, 178
from activated neutrophils 175
H_2O_2 175
HOCl 175
hydroxyl radical 175
inhibition for cell reliability 173, 178
methionine scavenging 177, 178
role in carcinogenesis 189
singlet oxygen 175
superoxide anion 175
Recombinant protein design, application to OLX-209 118
Rheumatoid arthritis, MTX treatment 399
Ribonucleotide reductase (EC 1.17.4.1) and HU 57

Salvage enzymes
exploitation in chemotherapy 13–15
rate-limiting step 13
Sarcoplasmic reticulum (SR)
HOCl on
ATP hydrolysis 177
Ca^{2+}transport 177
antioxidant protection 178
phosphorylation protection 178, 179
membrane microviscosity measurement 173, 176
membrane modification during oxidation 175
Serine hydroxymethyltransferase (EC 2.1.2.1) in thymidylate synthesis cycle 402
Serum response element (SRE)
in cotransfection studies of HC-11 cells 262, 263
in c-*fos* transcription 264, 266
Signal transduction
CKII role in 226
in UV response 383
components involved 387
hypothetical scheme 390
MAP-kinase involvement 386, 388
PKCs and *ras* genes 257
Single chain antibody region of OLX-209 120
Src dominant negative mutant on UV response 387, 388, 391
Steroidogenesis hormonal control of HSL 355
Superoxide dismutase (EC 1.15.1.1)
stimulation by thyroid hormone 180
surface residue assignments 281
Suramin blocking of UV responses 389

T cell receptor, relation to MHC class II 145, 152
Taurocholate
ATP-dependent transport
inhibition by CsA 373–375
inhibition by PSC 833 373–375
measurement 372, 373
hepatobiliary elimination *in vivo* CsA on 376
Taxol, absence of effect on bone marrow enzymes 84
Testosterone on GS in hepatocytes 35, 37
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD)

action in Ah receptor model 166
binding to dioxin receptor 160
induction of AHH activities in Hepa-1 mutants 163
12-O-Tetradecanoylphorbol-13-acetate (TPA)
activation of protein kinases 257
induction of c-*fos* 261
PKC requirement 264
ternary complex factor (TCF) requirement 264
on *ras* induction of *fos* 262, 263
on transcriptional activation 265
Thymidine kinase, cytosolic (TK1, EC 2.7.1.21)
acivicin on 83
activity in bone marrow, MTX on 75, 76
activity in growing and quiescent mouse cells 101, 102
activities in normal and neoplastic tissue 73, 74
assay 17
-CAT construct expression 262–266
cell cycle regulation 14, 19, 20, 23
cycloheximide on 77, 84
deoxynucleoside salvage in human cells 13, 14
expression in human cells and tissues 19
5-FU on 78, 79
in dTMP production 73
MTX on 78
properties 15
substrate specificity 1, 8, 14, 15, 23
$t_{1/2}$ 76, 84
tiazofurin on 81
Thymidine kinase, mitochondrial (TK2)
deoxynucleoside salvage in human cells 13, 14
expression in human cells and tissues 19
properties 15
substrate specificity 1, 8, 14, 15, 23
Thymidylate synthase (dTMP synthase, TS, EC 2.1.1.45)
activity in bone marrow, MTX on 72, 75, 76
activities in normal and neoplastic tissues 74
antifolate inhibitors 411
cycloheximide on 77, 84
5-FU on 78, 79
in thymidylate synthesis cycle 402
inhibition by ICI-D1694 64
MTX action on 72, 78
$t_{1/2}$ 76, 84
therapy target enzyme 57, 59
Thyroid hormones (TH)
antioxidant action 179, 182
in repair stimulation 182
mitochondrial target 180
on Ca^{2+} transport 184
on carcinogenic mechanisms 189, 190
on cell energy production 183
regulation and antioxidant enzymes 180
role in cell reliability 173, 188, 192
structure and antioxidant effect 180
thyroxine (T_4)
increase on antioxidant enzyme levels 180
inhibition of ROS 181, 182, 192
on ATPase gene expression 184
on DNA repair of X-ray damage 185, 186, 191
mode of action 187
3,5,3′-triiodothyronine (T_3)
binding in normal and transformed cells 191
inhibition of ROS 181, 182, 192
on Ca^{2+} transport 185
on GS in hepatocytes 35, 36
on oxidative phosphorylation 183
receptor proteins 183
requirement for superoxide dismutase synthesis 180
use in radiotherapy 190, 191
Thyroxine (T_4) *see* Thyroid hormones
Tiazofurin (TR, 2-β-D-ribofuranosylthiazole-4-carboxamide)
allopurinol synergism 79, 86
chemotherapy 79, 81
down-regulation of oncogenes 80, 81
induced differentiation 80, 81
non-targeted action 81–83, 85
on bone-marrow enzyme activities 79
on cellularity 81
on GPRT 79
on IMPDH 79, 81
on TdR kinase 81
targeted action 85, 86
with allopurinol on GTP concentration 79
Transcription factors
post-translational modification 384–386, 391
translocation to nucleus 129, 130
Transcriptional activation of protooncogenes 258
3,5,3′-Triiodothyronine (T_3) *see* Thyroid hormones
Trimethoprim
diffusion entry into cells 411
folate antagonist 410

structure 411
Trimetrexate (MTX analog)
diffusion entry into cells 410
structure 410
Tumor suppressor genes in 3Y1 cells, characterization 247–254
Tumorigenesis suppression with NO3 cDNA 253, 254

Ultraviolet irradiation (UVC): mammalian response 381–391
analysis of sequence of events 383
growth-factor-induced gene expression 384
signal transduction cascade 384, 387, 390
elicitation 381
induced changes in transcriptional rate 382
induced post-translational modification of transcription factors 384
c-Fos 385, 391
c-Jun 385, 386, 391
inhibition by suramin 389
site of signal generation 389, 390
Uracil dehydrogenase in 5-fluoropyrimidine pathways 57
Uracil/Ftorafur (UFT) site of chemotherapeutic action 57
Uracil phosphorylase in 5-fluoropyrimidine pathways 57

X-ray
damage repair, effect of thyroxine 185–187
induced changes in transcriptional rate 382
induced p53 accumulation 383
induced protein stabilization 382, 383
Xanthine-5′-monophosphate (XMP) marker for IMPDH activity 94, 95, 99–101
Xanthine oxidase (EC 1.2.3.2) activity elimination from IMPDH assay 95, 100
Xenobiotic responsive element
action in Hepa-1 mutants 163
binding to Ah receptor 163, 165, 167, 168
binding to ARNT protein 165, 167, 168